US20230001407A1 - Microporous substrate for use in a disposable bioassay cartridge - Google Patents
Microporous substrate for use in a disposable bioassay cartridge Download PDFInfo
- Publication number
- US20230001407A1 US20230001407A1 US17/886,710 US202217886710A US2023001407A1 US 20230001407 A1 US20230001407 A1 US 20230001407A1 US 202217886710 A US202217886710 A US 202217886710A US 2023001407 A1 US2023001407 A1 US 2023001407A1
- Authority
- US
- United States
- Prior art keywords
- microporous substrate
- micropores
- substrate
- microporous
- substrate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 227
- 238000004166 bioassay Methods 0.000 title description 17
- 239000000523 sample Substances 0.000 claims abstract description 71
- 239000000463 material Substances 0.000 claims abstract description 27
- 239000012491 analyte Substances 0.000 claims abstract description 23
- 230000003287 optical effect Effects 0.000 claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 230000000295 complement effect Effects 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229910052710 silicon Inorganic materials 0.000 claims description 10
- 239000010703 silicon Substances 0.000 claims description 10
- 239000004033 plastic Substances 0.000 claims description 7
- 230000002787 reinforcement Effects 0.000 claims description 6
- 238000000465 moulding Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000004049 embossing Methods 0.000 claims description 2
- 238000005530 etching Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 abstract description 35
- 238000012545 processing Methods 0.000 description 95
- 239000011148 porous material Substances 0.000 description 68
- 239000003153 chemical reaction reagent Substances 0.000 description 59
- 239000012530 fluid Substances 0.000 description 45
- 108020004707 nucleic acids Proteins 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 17
- 238000009739 binding Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000027455 binding Effects 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- 239000002699 waste material Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 10
- 238000013022 venting Methods 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000712079 Measles morbillivirus Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 201000005505 Measles Diseases 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 238000000879 optical micrograph Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000007669 thermal treatment Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940098197 human immunoglobulin g Drugs 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000007826 nucleic acid assay Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000007836 assay cartridge Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/50273—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means or forces applied to move the fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/28—Constructional details, e.g. recesses, hinges disposable or single use
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/025—Align devices or objects to ensure defined positions relative to each other
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0621—Control of the sequence of chambers filled or emptied
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0684—Venting, avoiding backpressure, avoid gas bubbles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0689—Sealing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/143—Quality control, feedback systems
- B01L2200/147—Employing temperature sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0874—Three dimensional network
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0677—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers
- B01L2400/0683—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers mechanically breaking a wall or membrane within a channel or chamber
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/08—Regulating or influencing the flow resistance
- B01L2400/084—Passive control of flow resistance
Definitions
- the present disclosure relates to a microporous substrate with tapered micropores extending right the substrate with the openings on one side of the substrate being wider than openings on the opposed substrate surface.
- the microporous substrate is for use with a disposable cartridge and method to move fluids and carry out multiple bioassay steps within the cartridge.
- Typical cartridge devices for biological assays are interfaced with an instrument containing syringes or other types of positive displacement pumps in order to accurately meter liquid volumes required sequentially in a reaction zone within the disposable cartridge.
- This often also involves the integration of mechanical valves within the cartridge structure to control fluid flows.
- care must be taken in the design of the fluidic paths to eliminate the formation of air bubbles that can significantly interfere with accurate fluid transfer.
- Complex structures or bubble control mechanisms are introduced into the design to mitigate these issues. This introduces manufacturing complexity and increased cost of the cartridges which are often meant to be used in a disposable fashion.
- a microporous substrate for detection of surface bound target analyte molecules includes a microporous substrate material having opposed surfaces and micropores, the micropores having bound therein analyte specific receptors complementary to the target analyte molecules, the micropores having tapered walls extending through a thickness of the microporous substrate in which the micropores are wider near one surface of the microporous substrate compared to a width of the micropores on the opposed surface to increase the collection efficiency of light emitted from optical probes bound to target analyte molecules when the target analyte molecules are captured by the analyte specific receptors which is detected by a light detector spaced from the side of the microporous substrate facing the larger micropore openings compared to a light collection efficiency of light emitted from the optical probes when the micropores are straight and not tapered.
- the micropores may be progressively wider near one surface of the microporous substrate.
- the micropores may have a rectangular cross section.
- the micropores may have a square cross section, or they may have a circular cross section.
- the tapering of the micropore walls may be conical, spherical, or parabolic.
- micropore dimension on the side opposite the side of the widened micropores may be substantially smaller thereby providing structural stability.
- micropores may be of uniform dimensions and morphology.
- the microporous substrate may further comprise reinforcement ribs to provide structural stability, and the reinforcement ribs may be an integral part of the microporous substrate, or alternatively, they may be made in a form of a rigid supporting mesh.
- the microporous substrate may be attached to a supporting mesh placed on the surface of the microporous substrate having the smaller micropore openings.
- the microporous porous substrate may be placed between two supporting meshes placed on the opposite sides of the microporous substrate.
- the microporous substrate may have a thickness of between 0.15 to about 0.75 mm.
- the tapered surface of the micropores may be covered with a reflective coating.
- the microporous substrate may be made of silicon.
- the microporous substrate may be made of a material that is opaque such that light from one micropore cannot be transmitted to neighboring micropores with the microporous substrate.
- the microporous substrate may be made by performing electrochemical etching of silicon to manufacture the microporous substrate.
- the microporous substrate may be made by embossing or molding of a plastic material to manufacture the microporous substrate.
- the device, method disclosed herein is of particular use in the area of medical diagnostics (human and veterinary), food safety testing, monitoring of environmental and biological hazards and general measurement of biological species.
- the design can be adapted to carry out most common assay formats for both proteins and nucleic acids including sample preparation steps.
- FIG. 1 is a side elevational view of a pneumatically driven assay cartridge showing the core components.
- FIG. 2 shows a more detailed side view of the cartridge of FIG. 1 with liquids in the starting position.
- FIG. 3 is an enlarged view of the side view of FIG. 2 showing movement of the liquid (thick dark line within the capillary) from a reagent reservoir to an upper processing chamber under pneumatic control.
- FIG. 4 is similar to FIG. 3 showing movement of the liquid from the upper processing chamber to a lower processing chamber through a microporous substrate under pneumatic control.
- FIG. 5 shows the liquid in the cartridge being moved back into the upper processing chamber under pneumatic control.
- FIG. 6 A shows the liquid in the cartridge partially moved into a waste container after completion of the processing steps.
- FIG. 6 B shows a kit including a disposable cartridge along with a dedicated blister pack containing a plurality of assay reagents and a matching gasket with the packets containing the assay reagents being aligned with preselected reagent chambers.
- FIG. 7 is a photograph of an assembled cartridge showing five (5) reagent/sample chambers and a bulk reagent chamber connected to a central upper processing chamber.
- FIG. 8 shows a top view of a cartridge configured for both nucleic acid sample preparation and nucleic acid amplification (isothermal or polymerase chain reaction (PCR)) and multiplex detection of the products.
- FIG. 9 shows a partially disassembled view of the disposable cartridge sandwiched between an upper pneumatic block assembly interface and a lower thermal control assembly which form part of the instrument into which the cartridge is inserted.
- FIG. 10 is a partial cross-sectional view of the sandwiched structure of FIG. 9 showing a detector positioned to view the microporous substrate.
- FIGS. 11 A to 11 C show three (3) tapered pores with different angles of tapering. Smaller tapering angle (B compared to A) leads to deeper tapering. For small enough angles the tapering is continuous from one surface of the substrate to the other as shown in C.
- FIGS. 12 A and 12 B show optical microphotographs of the front and back surfaces of a silicon substrate with tapered pores according to the present disclosure. These optical micrographs show that the high porosity of the substrate on the side with widened pores ( FIG. 12 A ) and the lower porosity of the substrate on the opposite side ( FIG. 12 B ).
- FIGS. 13 A to 13 C show micro photographs of the substrates with pores of a different cross section with FIG. 13 A being circular, FIG. 13 B being square, and FIG. 13 C being polygonal.
- FIGS. 14 A to 14 C show the tapered pores with different angles of tapering and as a result with different depths of tapered portion of a pore, with the optical micrographs showing the cross sections of tapered pores with different angles of tapering 14 A, 14 B and the top view, 14 C of the substrate cross section of which is shown in FIG. 14 A .
- FIGS. 15 A and 15 B demonstrate the improvement in light transmission of a microporous substrate due to pore tapering.
- the same substrate is shown in FIGS. 15 A and 15 B when illuminated by the same diffuse light source.
- the widened part of the pores are facing the objective lens in FIG. 15 A
- the narrow part of pores are facing the objective lens in FIG. 15 B .
- the spots on the substrates are regions in which the pores of the substrate have been blocked with probe solutions that have dried in the pores.
- FIGS. 16 A to 16 C illustrate the mechanisms contributing to light collection improvement, with 16 A showing the effect of increasing of the effective depth; 16 B showing the effect of an increase in the collection angle; and 16 C showing the effect of increase of surface area.
- FIG. 17 shows the results of calculation of light collection efficiency as a function of pore depth for a straight 8 um (micrometers) pore (plot A) and a pore with tapered walls (plot B).
- FIG. 18 shows the results of experimental comparison of signal intensities measured with a substrate with straight pores and with tapered pores.
- FIG. 18 confirms the expected 40% improvement of light collection efficiency according to disclosure.
- FIG. 19 A shows another embodiment of the flow-through chip substrate with cylindrical pores with conical tapering.
- FIG. 19 B shows a section of a single pore of the embodiment of FIG. 19 A .
- FIG. 20 A shows another embodiment of the flow-through chip substrate with cylindrical pores with spherical tapering.
- FIG. 20 B shows a section of a single pore of the embodiment of FIG. 20 A .
- FIG. 21 A shows another embodiment of the flow-through chip substrate with cylindrical pores with parabolic tapering.
- FIG. 21 B shows a section of a single pore of the embodiment of FIG. 21 A .
- FIG. 22 A shows a first embodiment of an arrangement of the tapered cylindrical pores in the microporous substrate.
- FIG. 22 B shows a second embodiment of tapered cylindrical pores in the microporous substrate being more closely packed than the arrangement of FIG. 22 A with enhanced light collection efficiency.
- FIG. 23 shows an embodiment of the flow-through chip substrate with the high-efficiency microporous substrate on the left hand side reinforced by a frame for structural stability, shown on the right hand side of the figure.
- FIG. 24 shows another embodiment of a flow-through chip substrate for improved optical detection sensitivity with a high-efficiency microporous substrate reinforced by two frames placed on the opposite sides of the substrate for structural stability.
- FIG. 25 A shows results of a nucleic acid bioassay conducted using the assembled cartridge shown in FIG. 7 .
- FIG. 25 B shows the chemiluminescent image of the microporous substrate contained within the assembled cartridge shown in FIG. 7 at the conclusion of the nucleic acid bioassay
- FIG. 26 shows results of a protein bioassay conducted using the assembled cartridge shown in FIG. 7 .
- FIG. 27 A shows results of a sample preparation using a microporous substrate forming part of the present cartridge.
- FIG. 27 B shows the chemiluminescent image of a microporous substrate used to detect residual protein analytes in a solution processed by a separate microporous substrate configured for sample preparation.
- FIG. 27 C shows the chemiluminescent image of a microporous substrate used to detect residual protein analytes in a solution prior to processing by a separate microporous substrate configured for sample preparation.
- the terms, “comprises” and “comprising” are to be construed as being inclusive and open ended, and not exclusive. Specifically, when used in the specification and claims, the terms, “comprises” and “comprising” and variations thereof mean the specified features, steps or components are included. These terms are not to be interpreted to exclude the presence of other features, steps or components.
- exemplary means “serving as an example, instance, or illustration,” and should not be construed as preferred or advantageous over other configurations disclosed herein.
- the terms “about” and “approximately” are meant to cover variations that may exist in the upper and lower limits of the ranges of values, such as variations in properties, parameters, and dimensions. In one non-limiting example, the terms “about” and “approximately” mean plus or minus 10 percent or less.
- Cartridge 100 configured to facilitate movement of fluids without the need for any internal valves or metering devices.
- the design is amenable to injection molded manufacturing lowering cost for large volume manufacturing.
- Cartridge 100 includes a first reagent chamber 10 which holds a liquid reagent or sample, and a second reagent chamber 12 which holds a second liquid reagent.
- Cartridge 100 includes a lower processing chamber 16 which has a volume equal to or exceeding the maximum liquid capacity of upper processing chamber 14 and is designed to minimize the space between the bottom inner surface of chamber 16 and the bottom surface of a microporous substrate 18 located within chamber 16 .
- Cartridge 100 includes an outlet chamber 20 with a volume greater than all of the reagents and samples combined.
- First reaction chamber 10 includes a pneumatic port 26 which is configured to provide negative differential pressure, positive differential pressure or vent under external system control to chamber 10 .
- Upper processing chamber 14 includes a pneumatic port 28 which is configured to provide negative differential pressure, positive differential pressure or vent under external system control to upper processing chamber 14 .
- Second reaction chamber 12 includes a pneumatic port 30 which is configured to provide negative differential pressure, positive differential pressure or vent under external system control to chamber 12 .
- Lower processing chamber 16 includes a pneumatic port 34 which is configured to provide negative differential pressure, positive differential pressure or vent under external system control to lower processing chamber 16 .
- outlet chamber 20 includes a pneumatic port 36 configured to provide negative differential pressure, positive differential pressure or vent under external system control to outlet chamber 20 .
- Pneumatic ports 26 , 28 , 30 , 34 and 36 may incorporate flexible diaphragms in their respective pneumatic conduits which can be used to isolate a given chamber from a pneumatic source while allowing a flux of gas through the conduit which is limited by the deformation of the diaphragm. Upon application of pneumatic pressure, gas will flow through the conduit until the back-pressure of the diaphragm equals the applied pneumatic pressure.
- Such flexible diaphragms are disclosed in U.S. Pat. No. 7,470,546, which is incorporated herein by reference in its entirety.
- flexible diaphragms may be incorporated into pneumatic ports 28 and 34 in FIG. 1 so that when a positive pneumatic pressure is applied to port 28 gas flows into upper processing chamber 14 until the diaphragm deforms enough to create a back pressure equal to the applied pressure.
- the gas entering the upper processing chamber 14 causes the liquid to flow through the microporous substrate 18 into lower processing chamber 16 , and air flows through port 34 and deforms the diaphragm in port 34 which would be vented to the atmosphere.
- port 34 is vented to the atmosphere there would be no passage of material between the interior of the cartridge 100 and the environment. This configuration permits back-and-forth transport of liquid across the microporous substrate 18 by the periodic application of pressure to port 28 which can be vented to the atmosphere when pressure is not applied.
- the microporous substrate 18 serves as an interface between processing chambers 14 and 16 and has a size and shape configured to prevent fluid from passing between processing chambers 14 and 16 other than through the microporous substrate 18 when the critical pressure is exceeded.
- Head spaces 22 are produced in lower processing chamber 16 due to microporous substrate 18 projecting into lower processing chamber 16 . While FIG. 1 shows two (2) head spaces 22 it will be understood that the cartridge may be configured to have only one. The direction of flow depends on the sign of the differential pressure between chambers 14 and 16 .
- Lower processing chamber 16 includes an optical window 40 which forms part of the lower surface of this lower processing chamber 16 to allow imaging of the microporous substrate 18 from outside the device cartridge 100 .
- microporous substrate 18 is a rigid substrate disposed in a rigid plane parallel to the image plane of the imaging device such that it does not move or is not displaced which would result in poor quality images being detected. Preferred properties and structure of rigid microporous substrate 18 will be discussed hereinafter.
- Upper process chamber 14 includes a solid support zone 44 which is the space immediately above the microporous substrate 18 which can be occupied by a solid support material of a larger size than the pores in the microporous substrate 18 such that the material is retained in zone 44 since it cannot pass through the microporous substrate 18 .
- the support material is capable of binding analytes of interest or acting as a support for reactions between bound and soluble materials.
- a capillary flow channel 48 connects reagent chamber 10 with the upper processing chamber 14 and is designed with an inner diameter sized to prevent flow in either direction until a differential pressure is applied exceeding a preselected critical level to permit flow between the chambers 10 and 14 .
- a capillary flow channel 50 connects reagent chamber 12 with the upper processing chamber 14 and is designed with an inner diameter sized to prevent flow in either direction until a preselected differential pressure is applied exceeding the critical level to permit flow between the chambers 12 and 14 .
- a capillary flow channel 52 connects lower processing chamber 16 with the outlet chamber 20 and is designed with an inner diameter sized to prevent flow in either direction until a preselected differential pressure is applied exceeding the critical level to permit flow.
- the capillary inner diameter could be selected from the range of 50 to 500 microns to provide critical pressures of 0.1 to 0.5 psi.
- Flow is effected from one chamber to the next by applying pressure to the originating chamber containing the fluid through the pneumatic port mounted on that chamber while simultaneously venting the destination chamber to which the capillary channel is connected through the pneumatic port mounted on that chamber.
- negative differential pressure can be applied to the destination chamber while simultaneously venting the originating chamber. In both cases a sufficient pressure differential must be provided to overcome the resistance of the channel and allow flow to occur.
- the differential pressure between these chambers can be changed from positive to negative and back to positive. This will change the direction of fluid flow.
- Reagent chambers 10 and 12 may contain liquid reagents or dried reagents for dissolution in the device by transferring a solution from another chamber.
- One or more of the reagent chambers 10 and 12 may be designed to accept the introduction of a sample or other material from an external source. It is noted that while only two (2) reagent chambers 10 and 12 are shown connected to upper processing chamber 14 , more could be included depending on the application at hand.
- Each reagent chamber 10 and 12 is provided with the port 26 for chamber 10 and port 30 for chamber 12 which can be interfaced with an external pneumatic system capable of providing one or more of positive or negative pressures or venting to a given chamber under external control.
- the upper processing chamber 14 is provided with port 28 which can also be interfaced with an external pneumatic system capable of providing one or more of positive or negative pressures or venting to the chamber under external control.
- each capillary channel 48 , 50 and 52 is selected to only permit flow through the channel from one chamber to the other when a differential pressure exceeding the critical pressure is applied.
- the length of the of the channel may be designed in the range of 5 to 30 mm in combination with the selected inner diameter in order to control the time required to transfer the full reagent volume between chambers in 1 to 60 seconds using applied pressures in the range of 0.1 to 1.5 psi.
- the internal diameter of each capillary channel 48 , 50 and 52 can be constant along the channel. Alternatively, a part of the channel 48 , 50 and 52 may have a smaller diameter (e.g., 50-500 um) and the rest of the channel may have a larger diameter (e.g., 500 um-2 mm). This type of channels 48 , 50 and 52 allow independent selection of the critical pressure and flow rate.
- the upper processing chamber 14 is sized to exceed the total volume of reagents or sample fluids that may be transferred to the upper processing chamber 14 at any time.
- capillary channel 48 connecting reagent chamber 10 to upper processing chamber 14 and capillary channel 50 connecting reagent chamber 12 to upper processing chamber 14 are positioned so that they terminate in the upper portion of the upper processing chamber 14 such that all are above the maximum level of liquid reached in the chamber.
- the bottom of the upper processing chamber 14 is composed of the microporous substrate 18 connected to the body of the chamber 14 in such a way that fluids can only exit through the bottom of the chamber 14 by passing through the microporous substrate 18 when the differential pressure exceeds the critical pressure.
- the upper processing chamber 14 may also contain the solid support 44 in the form of beads, particles, gels, or other similar materials that are capable of binding materials of interest from fluids within the chamber or acting as a support for bound materials to interact with materials contained in the fluid. These solid support materials 44 are of sufficient size that they are retained by the microporous substrate 18 and do not restrict flow through the substrate 18 .
- the microporous substrate 18 may also be composed of a material or modified in such a way as to act as a solid support capable of binding materials of interest from fluids that pass between the upper processing chamber 14 and the lower processing chamber 16 or acting as a support for bound materials to interact with materials contained in the fluid.
- the microporous substrate 18 is constructed of material containing pores selected to provide a uniform resistance to flow across its entire surface such that at a defined pressure differential across the substrate 18 , fluids will pass through the pores but gases (e.g., air) will not.
- the properties of the pores are selected such that the resistance to flow will not be overcome by the weight of liquids in the upper processing chamber 14 or allow capillary action to draw fluids completely through the pores in substrate 18 .
- the properties of the microporous substrate 18 may optionally be selected to require a pressure differential to initiate flow that is in the same range as that required to initiate flow through capillaries 48 , 50 and 52 in order to simplify design of the external pneumatic system.
- Flow between the upper processing chamber 14 and the lower processing chamber 16 is effected by applying pressure to the upper processing chamber 14 containing the fluid while simultaneously venting the lower processing chamber 16 separated by the microporous substrate 18 .
- negative pressure can be applied to the lower chamber 16 while simultaneously venting the upper chamber 14 .
- the pressure differential must be provided in a range that is sufficient to overcome the resistance of the pores in the substrate 18 and allow flow of liquids to occur but below that required to overcome the resistance to the flow of air through the pores.
- the process may be reversed to effect flow in the opposite direction to allow repeated contact with the substrate 18 and any solid support 44 contained in the upper chamber 14 as well as to provide efficient mixing.
- the lower processing chamber 16 is provided with two or more ports 34 (only one is shown in FIG. 1 ) which can be interfaced with an external pneumatic system capable of providing one or more of positive or negative pressures or venting to the chamber 16 under external control.
- the lower processing chamber 16 has a volume equal to or greater than the maximum volume of reagents or sample fluids that may be transferred from the chamber 16 at any time.
- the base of the lower processing chamber 16 is positioned in close proximity to the lower surface of the microporous substrate 18 while additional volume can be provided by extending a portion of the chamber 16 above the outer walls of the upper processing chamber 14 to form a headspace 22 .
- the lower surface of the lower processing chamber 16 which includes the optically transparent window 40 which allows for imaging of the lower surface of the microporous substrate 18 using for example a charge coupled device (CCD) camera or other suitable optical sensor.
- CCD charge coupled device
- the lower processing chamber 16 is connected to one or more outlet chambers 20 by one or more capillary channels 52 extending from the lowest point of the lower processing chamber 16 and terminating in the upper section of the outlet chamber 20 at a point above the maximum level of liquid to be contained in the outlet chamber 20 . At least one of these capillary channels 52 is positioned at the lowest level of the chamber 16 to allow substantially all of the liquid in the chamber 16 to be removed through channel 52 .
- One outlet chamber 20 may be used for waste containment in which case it is sized with a volume greater than the sum of all the fluids that need to be transferred from the lower processing chamber 16 .
- Another outlet chamber (not shown) may be used to transfer fluids to additional downstream chambers for further processing, depending on the tests to be performed.
- the microporous substrate 18 alone or in combination with the solid support 44 may be used to bind components in the fluid, and the bound components may be separated from the bulk fluid, washed, modified or copied, serve as binding agents for additional components, recovered for further use or any combination of these steps by the sequential transport of at least one fluid from a chamber on the device.
- the microporous substrate 18 may be designed to bind different substances in the fluid at different regions of the substrate 18 , substances bound at different regions of the substrate 18 are subsequently detected and/or quantified.
- a single device 100 may contain one or more processing zones (two are shown as processing chambers 14 and 16 but more could be included) which uses it's integral microporous substrate 18 to accomplish different functions including analyte capture (nucleic acid, protein, small molecule other biological or chemical entities), modification of captured analyte (replication, extension, amplification, labeling, cleavage, hydrolysis), modification of soluble analytes through immobilized enzymes or catalysts, retention of solid matrix for higher capacity capture (beads, particles, gels), detection and/or quantitation of one or more captured analytes through optical imaging (colorimetric, fluorescent, chemiluminescent, bioluminescent).
- the microporous substrate 18 also acts as a fluid control device necessary to carry out these functions.
- FIGS. 2 to 6 show side views of an actual cartridge produced using plastic in which a central plastic cartridge reagent plate 82 is sandwiched between an upper cartridge plate 80 and a lower cartridge plate 84 .
- FIG. 7 shows a photograph of an assembled cartridge and FIGS. 2 to 6 may be considered cross sections taken from FIG. 7 .
- FIGS. 2 and 3 illustrate the dispensing of a liquid reagent or sample into the upper processing chamber 14 .
- the liquid reagent or sample 60 is loaded into the reagent chamber 10 prior to the assay through a reagent/sample entry port 64 and then the port 64 is closed.
- a pressure of ⁇ 1 psi is applied to the chamber 10 containing the liquid 60 via port 26 while port 28 connected to the upper processing chamber 14 is vented creating a pressure differential allowing the reagent to flow through the reagent capillary channel 48 into upper processing chamber 14 .
- the liquid 60 falls to the bottom of the upper processing chamber 14 and covers the integral microporous substrate 18 . Any excess air is allowed to vent through port 28 .
- This method of dispensing fluids is similar for all other reagent chambers used in the assay, with the exception of a bulk wash buffer (not shown) which is stored in a larger reservoir and metered through a capillary channel on a timed basis so that a precise volume can be delivered during dispensing.
- a bulk wash buffer (not shown) which is stored in a larger reservoir and metered through a capillary channel on a timed basis so that a precise volume can be delivered during dispensing.
- a differential pressure is created by applying pressure through port 28 , while venting to atmosphere through port 34 . All other ports are closed during cycling. Fluid 60 travels from the upper processing chamber 14 into the lower process chamber 16 and headspace 22 .
- fluid 60 may be returned to the upper processing chamber 14 by reversing the process.
- a differential pressure is created by applying pressure to port 34 while simultaneously venting to atmosphere through port 28 .
- evacuation of the fluid from the lower processing chamber 16 is effected by applying a negative pressure through port 36 on chamber 20 while venting to atmosphere through port 34 .
- This allows air to enter through the lower processing chamber 16 headspace 22 and liquid 60 to travel though a distal waste capillary channel 66 from one side of lower chamber 16 coupled to a waste inlet 76 which empties into chamber 20 and a proximal waste capillary 70 coupled to a proximal waste outlet 72 exiting from the other side of chamber 16 coupled to a waste outlet 78 which empties liquid 60 into chamber 20 .
- FIG. 6 B shows an embodiment which is a kit including a disposable cartridge 100 along with a dedicated blister pack 130 containing a plurality of packets 134 containing selected liquid assay reagents and a matching gasket 132 with the packets 134 containing the assay reagents being aligned with preselected reagent chambers in plastic cartridge reagent plate 82 .
- the assembled cartridge 100 with upper cartridge plate 80 includes the packets 134 partially projecting into their corresponding reagent chambers.
- applying pressure via the pneumatic system coupled to the pneumatic ports on plate 80 (not shown) of the various chambers results in rupturing of frangible seals in the blister pack resulting in the reagents flowing into their respective chambers.
- the gasket 132 provides a liquid and gas seal between chambers. Additional solid reagents may be deposited into preselected reagent chambers within plastic cartridge reagent plate 82 prior to assembly of cartridge 100 , providing flexibility in the customization of reagent selection for desired biological assays and simplifying storage and transport requirements.
- FIG. 7 is a photograph of an assembled cartridge showing five (5) reagent/sample chambers 10 connected to a central upper processing chamber 14 . This photograph shows the cartridge without the pneumatic connection to the cartridge.
- a nucleic acid bioassay ( FIG. 25 ) and a protein bioassay ( FIG. 26 ) were conducted using the assembled cartridge shown in FIG. 7 .
- nucleic acids usually requires processing steps to isolate nucleic acids and to derive labelled copies of them for subsequent detection. Many applications require the analysis of many different target sequences, and high analytical sensitivity is often required. Furthermore, automated, cost-effective systems will be required so that relatively unskilled people will be able to perform the tests reliably for routine clinical testing.
- Purification and amplification of multiple nucleic acids targets can be performed by capturing the nucleic acids on a solid support and performing a series of incubation and washing steps on the support to produce derivatives of the nucleic acids that can be analyzed by hybridization on nucleic acid probes arrayed on the microporous substrate.
- FIG. 8 and its included legend shows a top view of a configuration of a bioassay cartridge 200 which incorporates design of cartridge 100 but is configured for both nucleic acid sample preparation and nucleic acid amplification (isothermal or polymerase chain reaction (PCR)) and multiplex detection of the products.
- Cartridge 200 is configured for both sample preparation using one microporous support 18 in processing chamber 209 and reaction product detection using a second porous substrate 18 in processing chamber 224 each consisting of an upper processing chamber 14 and a lower processing chamber 16 separated by microporous substrate 18 .
- Cartridge 200 provides for a sample inlet 208 , a means to mix the sample with a lysis or pretreatment buffer 210 , a processing chamber 209 containing microporous substrate 18 in which capture and modification of nucleic acids from the sample can be performed using dried or liquid reagents supplied from chambers 205 , 207 , 201 , 202 , 203 , 204 , or 206 . Fluids from the processing chamber 209 may be transferred to waste chamber 226 or in the case of fluid containing the derivative nucleic acids to a thermal treatment chamber 211 or intermediate chamber 212 .
- Chamber 212 may be used to mix the fluid with dried or liquid reagent in chamber 213 . Subsequently, the fluid may be processed through one or more temperature treatment chambers 214 , 216 where isothermal or thermal cycling amplification may take place. These thermal treatment chambers 211 , 214 , 216 are isolated from the bulk of the cartridge by thermal insulating zones 215 and controlled by the application of heat or cooling from an external thermal control assembly 108 ( FIG. 9 ).
- the processed liquid containing the amplified derivative nucleic acids can then be transferred to an intermediate chamber 218 , mixed with an appropriate binding buffer 219 for hybridization to the microporous substrate 18 , located in sample processing chamber 224 where the derivative nucleic acids are detected on bound nucleic acid probes immobilized in specific locations on the microporous substrate 18 .
- a series of steps as previously described are carried out using reagents from adjacent chambers 217 , 220 , 222 , 223 , 225 with spent fluids being directed to waste chamber 227 .
- pneumatic pressure applied through ports located on each chamber is used to control fluid movement.
- an image of the microporous substrate 18 is captured with a CCD camera with integral lens 120 ( FIG. 10 ) located below the optical window 40 ( FIG. 1 ). This image is analyzed for intensity of light measured across the microporous substrate and correlated to the specific regions known to contain the immobilized probes. This information is used to calculate the presence or absence or quantity of specific nucleic acids in the original sample.
- cartridges may be configured to have multiple reagent/sample chambers/reservoirs, upper and lower processing chambers 14 and 16 , and waste chambers 20 .
- waste chamber 20 may in fact be an intermediate chamber accepting reaction products from a first processing station including first and second upper and lower processing chambers 14 and 16 with chamber 20 forming a sample chamber for a second series of upper and lower processing chambers 14 and 16 .
- cartridge 200 may be configured with additional features to permit numerous intermediate processing steps to be carried out between the first and second set of upper and lower processing chambers 14 and 16 . Non-limiting examples of these intermediate processing steps may include mixing, dilution, incubation, thermal treatment including but not limited to thermal cycling to give a few examples.
- cartridge 200 may include a decontamination chamber 228 containing a cleansing agent selected to destroy or neutralize harmful products of the assay or sample.
- the system of FIG. 8 utilizing the disposable cartridge disclosed herein is very amenable to performing the above noted nucleic acid assay such as that disclosed in United States Patent Publication Serial No. US2018-0057855A1, which is incorporated herein by reference in its entirety, and which is a national phase entry patent application of PCT/2016/050367 filed on Mar. 29, 2016.
- the present disclosure provides a cartridge which in an embodiment comprises two different microporous substrates each with upper and processing chambers, one of which is a solid support for purification of multiple target nucleic acids and processing of the target nucleic acids to produce derivative nucleic acids, and the other of which is a porous substrate on which the derivative nucleic acids are detected on bound nucleic acid probes.
- the present cartridge in conjunction with an instrument designed to operate it, will accept samples and provide clinically relevant information without user intervention after inserting the samples.
- the present disclosure provides embodiments of a disposable cartridge comprising two different microporous substrates 18 each with associated upper and lower processing chambers 14 and 16 , one of the coupled chambers 14 and 16 may be used for mixing of the sample with a diluent, and the second of the coupled chambers 14 and 16 includes a flow-through microporous substrate 18 on which the proteins are detected by immuno-binding reactions.
- the first microporous substrate 18 may contain immobilized binding agents that would bind specific components in the sample. For example, interfering substances might be removed by binding to the first microporous substrate 18 before the immuno-binding step on the second porous substrate 18 is performed.
- low abundance substances may be concentrated from a large volume by binding to the first microporous substrate 18 and then being released in a smaller volume at higher concentration before the immuno-binding step on the second microporous substrate 18 is performed in order to improve overall sensitivity of detection.
- FIG. 9 shows a partially exploded view of the disposable cartridge 104 sandwiched between an upper pneumatic block assembly interface 106 and a lower thermal control assembly 108 which form part of the instrument into which the cartridge 104 is inserted.
- Pneumatic interface 106 includes all the requisite pneumatic coupling components, tubes and the like needed to couple to the pneumatic ports of the cartridge 104 . All these components are housed in interface 106 and do not form part of the disposable cartridge 104 .
- thermal control assembly 108 contains all requisite features such as heaters, temperatures sensors and associated controllers, microprocessors and the like to control the temperature in selected zones of the cartridge 104 .
- the thermal control assembly 108 includes a central aperture 110 which when assembled with cartridge 104 aligns with optical window 40 to allow imaging of the porous substrate 18 .
- FIG. 10 is a partial cross-sectional view of the sandwiched structure of FIG. 9 showing detector 120 positioned to view this microporous substrate 18 in the assembled system.
- Detector 120 which includes an appropriate objective lens is configured to image the bottom side of microporous substrate 18 to detect the presence of colorimetric, fluorescent, chemiluminescent, or bioluminescent signals.
- a preferred material from which the microporous substrate 18 is produced is silicon which is rigid and opaque to chemiluminescent emission. This opacity prevents crosstalk between different pores of the substrate and hence prevents crosstalk between closely spaced regions on the substrate with different binding agents. This permits the analysis of many analytes in a small device, since different binding agents can be arranged in close proximity.
- the substrate may contain pores with a size in the range of 1 to 15 microns with wall thicknesses between pores ranging from 1 to 5 microns.
- the two opposed sides have different pore sizes.
- the side of the substrate 18 from which light is collected to enable detection and analysis has substantially wider pores as can be seen in FIGS. 11 A to 14 C , and this side is the side facing into lower reaction chamber 16 and faces the optical window 40 from which the detector 120 ( FIG. 10 ) is spaced.
- the walls of the pores at this surface are tapered rather than being normal to the surface. This geometry presents a greater surface area to the detection optics and less restriction to the transmission of light from within the pores.
- the substrate 18 has adequate strength and structural stability for flow-through applications due to the small pore size on the opposite side and there is a substantial amount of material between the pores.
- FIGS. 15 A and B demonstrate the remarkable asymmetric optical properties of the substrate.
- FIGS. 15 A and 15 B demonstrate the improvement in light transmission of a porous substrate due to pore tapering.
- the same substrate is shown in 15 A and 15 B when illuminated by the same diffuse light source.
- the widened part of the pores are facing the objective lens in FIG. 15 A and the narrow part of the pores are facing the objective lens in FIG. 15 B .
- the spots on the substrates are regions in which the pores of the substrate have been blocked with probe solutions that have dried in the pores.
- Tapering of the pore walls provides improvement of light collection due to increase of the depth from which the light can be collected, increase of the emitting surface area of the upper portion of a pore and increase of a collection angle.
- FIGS. 16 A to 16 C These mechanisms of light collection efficiency are illustrated in FIGS. 16 A to 16 C with 16 A showing the effect of increasing of the effective depth; 16 B showing the effect of an increase in the collection angle; and 16 C showing the effect of increase of surface area.
- FIG. 17 shows the results of calculation of light collection efficiency as a function of pore depth for a straight 8 um pore (plot A) and a pore with tapered walls (plot B).
- the parameters used for this evaluation are: 1) the width of non-tapered portion of a pore is 8 um; 2) the thickness of a wall between pores is 4 um; 3) the substrate thickness is 350 um; 4) tapering angle 2 degrees; 5) the diameter of the objective lens is 25.4 mm; and 6) the working distance of the objective lens is 50 mm.
- the substrate 18 using silicon has been used to manufacture flow-through chips on which different probes have been immobilized in discrete regions or spots.
- the same flow-through chips have been manufactured with a highly microporous silicon substrate with pore walls normal to the surface.
- the signal intensities were approximately 40% greater with the substrate described in this invention ( FIG. 18 ).
- This experimental result confirms the theoretical evaluation of efficiency enhancement due to pore tapering.
- the enhanced optical detection sensitivity improves the sensitivity of assays performed on the chips and/or improves the throughput of the assay system.
- the suggested approach is not very sensitive to a particular selection of the tapering angle as long as the inner plane of a pore wall does not restrict light collection.
- the tapering angle can be selected in the range between 0.3 degrees (tapering of a pore wall along full pore depth) to approximately 14 degrees. Tapering with the angles outside of this range will still increase amount of collected light, but the improvement will be less pronounced. It is noted that selection of a particular tapering angle and depth of tapering can be additionally influenced by the process of substrate manufacturing, the selected pore size and membrane thickness.
- the geometry of pores does not need to be square. If the manufacturing process requires they may have a different cross section, for example, circular. In this case the pore is cylindrical (see FIGS. 19 A, 19 B to 21 A, 21 B inclusive). In this case the simplest form of tapering is conical as shown in FIGS. 19 A and 19 B .
- the light collection efficiency can be additionally increased by changing shape of tapering from conical to spherical (see FIGS. 20 A and 20 B ) or parabolic ( FIGS. 21 A and 21 B ).
- FIGS. 13 A to 13 C Pores of different cross section (circular, square, polygonal) were derived to practice: the micro photographs of such silicon substrates are shown in FIGS. 13 A to 13 C .
- the light collection efficiency can be additionally improved for a substrate with cylindrical pores by a denser arrangement of pores as shown in FIG. 22 B compared to the collection efficiency of the packed structure of FIG. 22 A .
- a reinforcement frame can be used to strengthen the substrate (see FIGS. 23 and 24 ).
- a substrate 300 can be attached to a single frame 310 made of ribs 304 with the single frame being integrally formed with the substrate 300 or, preferably sandwiched between two separate frames 324 and 326 (see FIG. 24 ), which are separate from the substrate 300 , to allow bidirectional application of pressure required to drive fluids through the porous substrate as described above without damaging of the substrate.
- the present disclosure provides a disposable sample handling cartridge for performing multiplex biological assays in which the cartridge is designed and configured to provide complex fluid processing without the need for active pumping and valving.
- the cartridge is readily produced using standard molding techniques, no nanostructrures are required and no precise tolerances are required.
- the movement of sample and reagent fluid is solely determined by application of differential pressures, which are correlated primarily with the properties of the sample substrate 18 , namely pore size and distribution in the substrate 18 , as well as the inner diameter of the capillary channels (e,g. 48).
- the cartridge disclosed herein advantageously contains no moving parts and is made of a small number of parts compared to current systems, which typically contain active pumps, active valves and the like.
- the cartridge disclosed herein may be used for, but is not limited to use in sandwich, or competitive immunoassay for protein antigen analysis; serology for antibody binding to immobilized antigens for allergy, autoimmune, infectious disease; nucleic acids measurement of DNA, RNA, mRNA, microRNA (miRNA) etc. to identify specific sequences whose presence or expression is correlated to presence or progress of disease, sequences that can be used to identify species of bacteria, fungi, viruses in a sample, sequences that indicated the presence of specific resistance genes in pathogens, measurement of copy number variations (CNV's) or specific gene variants or deletions that correlate to risk of disease, gene signatures used to type samples for forensic or identification purposes.
- CNV's copy number variations
- it may be used for small molecule measurements including drugs and environmental contaminants. It may also be used in multiple sample matrices including human and animal fluids and tissues, food and agricultural samples, environmental samples, cells and lysates of cells, and bioprocessing fluids.
- Non-limiting exemplary uses of the disposable cartridge disclosed herein will now be given using a nucleic acid assay and a protein assay.
- FIG. 25 A shows results of a nucleic acid bioassay wherein a sample containing biotin labelled PCR products representing copies of specific gene sequences from bacterial samples were processed using the cartridge shown in FIG. 7 .
- the microporous substrate 18 Prior to assembly of the cartridge, the microporous substrate 18 was functionalized in discrete regions to form analysis spots, each of approximately 200 um in diameter, with oligonucleotide probes containing sequences complementary to sequences known to occur in the amplified bacterial gene (+ve Probes 1, 2, 3, 4), sequences not known to occur in the amplified bacterial gene ( ⁇ ve Probes 1, 2) or a sequence complementary to an artificial oligonucleotide added to the sample (Fiducial).
- one blank spot where no oligonucleotide probe was immobilized was used as a control to measure background signal. 5 individual reagent wells 10 and a bulk chamber 87 were used.
- the reagent chambers were individually loaded with blocking buffer, hybridization buffer, sample, streptavidin-HRP and chemiluminescent substrate respectively.
- the bulk reservoir 87 was loaded with wash buffer.
- Reagents were transferred to the upper processing chamber in individual steps as illustrated in FIG. 3 . Each liquid was then transferred to the lower processing chamber as illustrated in FIG. 4 and then returned to the upper processing chamber as illustrated in FIG. 5 .
- the reagent was removed to waste chamber as illustrated in FIG. 6 .
- an aliquot of wash buffer from bulk chamber 87 was similarly processed.
- the sequential steps accomplished blocking of the porous microporous substrate to prevent non-specific binding, hybridization of PCR products in the sample to the probes containing complementary sequences immobilized in discrete regions on porous substrate 18 , binding of streptavidin-HRP to the biotin label on captured PCR products, and introduction of a chemiluminescent substrate that could be processed by the captured HRP enzyme to produce a chemiluminescent emission in that specific region.
- FIG. 25 A shows the luminescent intensity for three repeats of the bioassay for the same sample. It will be noted that significant signals are observed on analysis spots formed by immobilizing probes containing complementary sequences to gene sequences expected in the sample (+ve Probes 1, 2, 3, 4), minimal signal is observed on analysis spots formed by immobilizing probes containing complementary sequences to gene sequences not expected in the sample ( ⁇ ve Probes 1, 2). As expected, no signal was observed on the blank analysis spot, and substantial signal was observed on the analysis spot containing a complementary sequence to the artificial oligonucleotide added to the sample prior to analysis.
- FIG. 26 shows results of protein bioassays on human serum or control buffer to determine the presence of antibodies against the measles virus carried out using the cartridge pictured in FIG. 7 .
- the microporous substrate 18 Prior to assembly of the cartridge, the microporous substrate 18 was functionalized in discrete regions to form analysis spots, each of approximately 200 um in diameter, with a deactivated measles virus preparation.
- Four reagent chambers were individually loaded with blocking buffer, sample, HRP labelled anti human immunoglobulin G and chemiluminescent substrate, respectively.
- the bulk reservoir 87 was loaded with wash buffer.
- Reagents were transferred to the upper processing chamber in individual steps as illustrated in FIG. 3 . Each liquid was then transferred to the lower processing chamber as illustrated in FIG. 4 and then returned to the upper processing chamber as illustrated in FIG. 5 . After repeating this cycle back and forth through the microporous substrate 18 as many times as required for each step the reagent was removed to waste chamber as illustrated in FIG. 6 . Between each step an aliquot of wash buffer from bulk chamber 87 was similarly processed.
- the sequential steps accomplished blocking of the microporous substrate to prevent non-specific binding, binding from the sample of any immunoglobulins containing regions that are specific to components of the measles virus immobilized in discrete regions on microporous substrate 18 , binding of anti-human immunoglobulin G antibody coupled to a HRP enzyme to any retained anti-measles immunoglobulins, and introduction of a chemiluminescent substrate that could be processed by the bound HRP enzyme to produce a chemiluminescent emission in that specific region.
- an image of the microporous substrate 18 was captured with a CCD camera 120 located below the optical window 40 .
- This image was analyzed for intensity of light measured across the microporous substrate 18 and correlated to the specific regions known to contain the immobilized virus.
- the chart in FIG. 26 shows the luminescence intensity recorded for three types of samples. It will be noted that significant signal corresponding to the presence of measles specific antibodies is observed from the serum sample drawn from a patient known to have immunity to the measles virus (positive serum). Significantly lower signal is observed from serum drawn from a patient known to have reduced immunity to the measles virus (negative serum). Minimal signal is observed from a control buffer sample that does not contain any measles specific antibodies.
- FIG. 27 A illustrates the results of a process that utilizes two different microporous substrates each with upper and processing chambers, one of which is a solid support for capture of protein analytes, and the other of which is a microporous substrate on which the protein analytes are detected on bound protein specific receptors.
- identical samples containing biotinylated mouse IgG analyte were cycled through a microporous substrate 18 that was functionalized with a rabbit anti-mouse antibody know to have a high binding affinity for mouse IgG (Treated sample) or cycled through a microporous substrate 18 that had not been functionalized, (Non-treated sample).
- the resulting fluid was then processed through a microporous substrate that had been functionalized in discrete regions to form analysis spots, each of approximately 200 um in diameter with either a rabbit anti-mouse antibody known to have a high binding affinity for mouse IgG or a biotinylated bovine serum albumin to serve as a reference spot. Washing, binding of streptavidin-HRP to any captured biotin-mouse IgG and immobilized biotin-BSA, and introduction of a chemiluminescent substrate that could be processed by the bound HRP enzyme to produce a chemiluminescent emission in that specific region were sequentially carried out.
- an image of the microporous substrate 18 was captured with a CCD camera 120 located below the optical window 40 .
- the intensity of each spot functionalized with rabbit anti-mouse IgG correlates with the amount of biotinylated mouse IgG analyte present in the solution.
- FIG. 27 A shows that the sample that had been processed by the first functionalized microporous substrate 18 (Treated) was almost completely depleted of mouse IgG analyte when processed on the second microporous substrate 18 used for detection. It can also be observed that the sample that had been processed by the first non-functionalized microporous substrate 18 (non-treated) exhibited high levels of mouse IgG analyte when processed on the second microporous substrate 18 used for detection.
- FIG. 27 B represents the signal captured by the CCD camera 120 from the second microporous substrate 18 for the treated sample. Significant signal is observed only on the reference biotinylated BSA analysis spots.
- FIG. 27 C represents the signal captured by the CCD camera 120 from the second microporous substrate 18 for the non-treated sample. Significant signal from the analysis spots for both the reference biotinylated BSA and the biotinylated mouse IgG can be observed.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Clinical Laboratory Science (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plasma & Fusion (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A microporous substrate for detection of surface bound target analyte molecules includes a microporous substrate material having opposed surfaces and tapered micropores extending through the substrate with the micropores having wider openings on one side of the substrate compared to the other side. The micropores have bound therein analyte specific receptors complementary to the target molecules. When a liquid sample containing the target analyte molecules with optical probes attached to the target molecules is flowed through the substrate, they bind to their complementary analyte specific receptors and emit light. This microporous substrate structure gives an increase in the collection efficiency of light emitted from optical probes when the light is detected by a light detector spaced from the side of the microporous substrate facing the larger micropores openings compared to a light collection efficiency of light emitted from the optical probes when the micropores are straight and not tapered.
Description
- This patent application is a US continuation patent application of U.S. Ser. No. 17/716,729 filed on Apr. 8, 2022, entitled MICROPOROUS SUBSTRATE FOR USE IN A DISPOSABLE BIOASSAY CARTRIDGE, which is incorporated herein in its entirety by reference.
- The present disclosure relates to a microporous substrate with tapered micropores extending right the substrate with the openings on one side of the substrate being wider than openings on the opposed substrate surface. The microporous substrate is for use with a disposable cartridge and method to move fluids and carry out multiple bioassay steps within the cartridge.
- Typical cartridge devices for biological assays are interfaced with an instrument containing syringes or other types of positive displacement pumps in order to accurately meter liquid volumes required sequentially in a reaction zone within the disposable cartridge. This often also involves the integration of mechanical valves within the cartridge structure to control fluid flows. In addition, care must be taken in the design of the fluidic paths to eliminate the formation of air bubbles that can significantly interfere with accurate fluid transfer. Complex structures or bubble control mechanisms are introduced into the design to mitigate these issues. This introduces manufacturing complexity and increased cost of the cartridges which are often meant to be used in a disposable fashion.
- In view of the trend toward point of use diagnostic testing, there is a need to integrate multiple functions/assay steps in a single cartridge on a cost effective basis consistent with mass production of the disposable cartridges. Therefore, it would be very beneficial to provide a disposable cartridge which integrates multiple functions with a minimum number of moving parts such as active pumps and valves in the field of automated point of use diagnostic bioassays.
- The present disclosure provides a microporous substrate for detection of surface bound target analyte molecules includes a microporous substrate material having opposed surfaces and micropores, the micropores having bound therein analyte specific receptors complementary to the target analyte molecules, the micropores having tapered walls extending through a thickness of the microporous substrate in which the micropores are wider near one surface of the microporous substrate compared to a width of the micropores on the opposed surface to increase the collection efficiency of light emitted from optical probes bound to target analyte molecules when the target analyte molecules are captured by the analyte specific receptors which is detected by a light detector spaced from the side of the microporous substrate facing the larger micropore openings compared to a light collection efficiency of light emitted from the optical probes when the micropores are straight and not tapered.
- The micropores may be progressively wider near one surface of the microporous substrate.
- The micropores may have a rectangular cross section.
- The micropores may have a square cross section, or they may have a circular cross section.
- The tapering of the micropore walls may be conical, spherical, or parabolic.
- The micropore dimension on the side opposite the side of the widened micropores may be substantially smaller thereby providing structural stability.
- The micropores may be of uniform dimensions and morphology.
- The microporous substrate may further comprise reinforcement ribs to provide structural stability, and the reinforcement ribs may be an integral part of the microporous substrate, or alternatively, they may be made in a form of a rigid supporting mesh.
- The microporous substrate may be attached to a supporting mesh placed on the surface of the microporous substrate having the smaller micropore openings.
- The microporous porous substrate may be placed between two supporting meshes placed on the opposite sides of the microporous substrate.
- The microporous substrate may have a thickness of between 0.15 to about 0.75 mm.
- The tapered surface of the micropores may be covered with a reflective coating.
- The microporous substrate may be made of silicon.
- The microporous substrate may be made of a material that is opaque such that light from one micropore cannot be transmitted to neighboring micropores with the microporous substrate.
- The microporous substrate may be made by performing electrochemical etching of silicon to manufacture the microporous substrate.
- The microporous substrate may be made by embossing or molding of a plastic material to manufacture the microporous substrate.
- The device, method disclosed herein is of particular use in the area of medical diagnostics (human and veterinary), food safety testing, monitoring of environmental and biological hazards and general measurement of biological species. The design can be adapted to carry out most common assay formats for both proteins and nucleic acids including sample preparation steps.
- A further understanding of the functional and advantageous aspects of the present disclosure can be realized by reference to the following detailed description and drawings.
- Embodiments will now be described, by way of example only, with reference to the drawings, in which:
-
FIG. 1 is a side elevational view of a pneumatically driven assay cartridge showing the core components. -
FIG. 2 shows a more detailed side view of the cartridge ofFIG. 1 with liquids in the starting position. -
FIG. 3 is an enlarged view of the side view ofFIG. 2 showing movement of the liquid (thick dark line within the capillary) from a reagent reservoir to an upper processing chamber under pneumatic control. -
FIG. 4 is similar toFIG. 3 showing movement of the liquid from the upper processing chamber to a lower processing chamber through a microporous substrate under pneumatic control. -
FIG. 5 shows the liquid in the cartridge being moved back into the upper processing chamber under pneumatic control. -
FIG. 6A shows the liquid in the cartridge partially moved into a waste container after completion of the processing steps. -
FIG. 6B shows a kit including a disposable cartridge along with a dedicated blister pack containing a plurality of assay reagents and a matching gasket with the packets containing the assay reagents being aligned with preselected reagent chambers. -
FIG. 7 is a photograph of an assembled cartridge showing five (5) reagent/sample chambers and a bulk reagent chamber connected to a central upper processing chamber. -
FIG. 8 shows a top view of a cartridge configured for both nucleic acid sample preparation and nucleic acid amplification (isothermal or polymerase chain reaction (PCR)) and multiplex detection of the products. -
FIG. 9 shows a partially disassembled view of the disposable cartridge sandwiched between an upper pneumatic block assembly interface and a lower thermal control assembly which form part of the instrument into which the cartridge is inserted. -
FIG. 10 is a partial cross-sectional view of the sandwiched structure ofFIG. 9 showing a detector positioned to view the microporous substrate. -
FIGS. 11A to 11C show three (3) tapered pores with different angles of tapering. Smaller tapering angle (B compared to A) leads to deeper tapering. For small enough angles the tapering is continuous from one surface of the substrate to the other as shown in C. -
FIGS. 12A and 12B show optical microphotographs of the front and back surfaces of a silicon substrate with tapered pores according to the present disclosure. These optical micrographs show that the high porosity of the substrate on the side with widened pores (FIG. 12A ) and the lower porosity of the substrate on the opposite side (FIG. 12B ). -
FIGS. 13A to 13C show micro photographs of the substrates with pores of a different cross section withFIG. 13A being circular,FIG. 13B being square, andFIG. 13C being polygonal. -
FIGS. 14A to 14C show the tapered pores with different angles of tapering and as a result with different depths of tapered portion of a pore, with the optical micrographs showing the cross sections of tapered pores with different angles of tapering 14A, 14B and the top view, 14C of the substrate cross section of which is shown inFIG. 14A . -
FIGS. 15A and 15B demonstrate the improvement in light transmission of a microporous substrate due to pore tapering. The same substrate is shown inFIGS. 15A and 15B when illuminated by the same diffuse light source. The widened part of the pores are facing the objective lens inFIG. 15A , and the narrow part of pores are facing the objective lens inFIG. 15B . The spots on the substrates are regions in which the pores of the substrate have been blocked with probe solutions that have dried in the pores. -
FIGS. 16A to 16C illustrate the mechanisms contributing to light collection improvement, with 16A showing the effect of increasing of the effective depth; 16B showing the effect of an increase in the collection angle; and 16C showing the effect of increase of surface area. -
FIG. 17 shows the results of calculation of light collection efficiency as a function of pore depth for a straight 8 um (micrometers) pore (plot A) and a pore with tapered walls (plot B). -
FIG. 18 shows the results of experimental comparison of signal intensities measured with a substrate with straight pores and with tapered pores.FIG. 18 confirms the expected 40% improvement of light collection efficiency according to disclosure. -
FIG. 19A shows another embodiment of the flow-through chip substrate with cylindrical pores with conical tapering. -
FIG. 19B shows a section of a single pore of the embodiment ofFIG. 19A . -
FIG. 20A shows another embodiment of the flow-through chip substrate with cylindrical pores with spherical tapering. -
FIG. 20B shows a section of a single pore of the embodiment ofFIG. 20A . -
FIG. 21A shows another embodiment of the flow-through chip substrate with cylindrical pores with parabolic tapering. -
FIG. 21B shows a section of a single pore of the embodiment ofFIG. 21A . -
FIG. 22A shows a first embodiment of an arrangement of the tapered cylindrical pores in the microporous substrate. -
FIG. 22B shows a second embodiment of tapered cylindrical pores in the microporous substrate being more closely packed than the arrangement ofFIG. 22A with enhanced light collection efficiency. -
FIG. 23 shows an embodiment of the flow-through chip substrate with the high-efficiency microporous substrate on the left hand side reinforced by a frame for structural stability, shown on the right hand side of the figure. -
FIG. 24 shows another embodiment of a flow-through chip substrate for improved optical detection sensitivity with a high-efficiency microporous substrate reinforced by two frames placed on the opposite sides of the substrate for structural stability. -
FIG. 25A shows results of a nucleic acid bioassay conducted using the assembled cartridge shown inFIG. 7 . -
FIG. 25B shows the chemiluminescent image of the microporous substrate contained within the assembled cartridge shown inFIG. 7 at the conclusion of the nucleic acid bioassay -
FIG. 26 shows results of a protein bioassay conducted using the assembled cartridge shown inFIG. 7 . -
FIG. 27A shows results of a sample preparation using a microporous substrate forming part of the present cartridge. -
FIG. 27B shows the chemiluminescent image of a microporous substrate used to detect residual protein analytes in a solution processed by a separate microporous substrate configured for sample preparation. -
FIG. 27C shows the chemiluminescent image of a microporous substrate used to detect residual protein analytes in a solution prior to processing by a separate microporous substrate configured for sample preparation. - Various embodiments and aspects of the disclosure will be described with reference to details discussed below. The following description and drawings are illustrative of the disclosure and are not to be construed as limiting the disclosure. Numerous specific details are described to provide a thorough understanding of various embodiments of the present disclosure. However, in certain instances, well-known or conventional details are not described in order to provide a concise discussion of embodiments of the present disclosure.
- As used herein, the terms, “comprises” and “comprising” are to be construed as being inclusive and open ended, and not exclusive. Specifically, when used in the specification and claims, the terms, “comprises” and “comprising” and variations thereof mean the specified features, steps or components are included. These terms are not to be interpreted to exclude the presence of other features, steps or components.
- As used herein, the term “exemplary” means “serving as an example, instance, or illustration,” and should not be construed as preferred or advantageous over other configurations disclosed herein.
- As used herein, the terms “about” and “approximately” are meant to cover variations that may exist in the upper and lower limits of the ranges of values, such as variations in properties, parameters, and dimensions. In one non-limiting example, the terms “about” and “approximately” mean plus or minus 10 percent or less.
- Unless defined otherwise, all technical and scientific terms used herein are intended to have the same meaning as commonly understood to one of ordinary skill in the art.
- Referring to
FIG. 1 , there is shown acartridge 100 configured to facilitate movement of fluids without the need for any internal valves or metering devices. The design is amenable to injection molded manufacturing lowering cost for large volume manufacturing.Cartridge 100 includes afirst reagent chamber 10 which holds a liquid reagent or sample, and asecond reagent chamber 12 which holds a second liquid reagent. - An
upper processing chamber 14 is provided having a volume greater than thefirst reagent chamber 10 orsecond reagent chamber 12.Cartridge 100 includes alower processing chamber 16 which has a volume equal to or exceeding the maximum liquid capacity ofupper processing chamber 14 and is designed to minimize the space between the bottom inner surface ofchamber 16 and the bottom surface of amicroporous substrate 18 located withinchamber 16.Cartridge 100 includes anoutlet chamber 20 with a volume greater than all of the reagents and samples combined. -
First reaction chamber 10 includes apneumatic port 26 which is configured to provide negative differential pressure, positive differential pressure or vent under external system control tochamber 10.Upper processing chamber 14 includes apneumatic port 28 which is configured to provide negative differential pressure, positive differential pressure or vent under external system control toupper processing chamber 14.Second reaction chamber 12 includes apneumatic port 30 which is configured to provide negative differential pressure, positive differential pressure or vent under external system control tochamber 12.Lower processing chamber 16 includes apneumatic port 34 which is configured to provide negative differential pressure, positive differential pressure or vent under external system control to lower processingchamber 16. Similarly,outlet chamber 20 includes apneumatic port 36 configured to provide negative differential pressure, positive differential pressure or vent under external system control tooutlet chamber 20. -
Pneumatic ports - More particularly, flexible diaphragms may be incorporated into
pneumatic ports FIG. 1 so that when a positive pneumatic pressure is applied toport 28 gas flows intoupper processing chamber 14 until the diaphragm deforms enough to create a back pressure equal to the applied pressure. The gas entering theupper processing chamber 14 causes the liquid to flow through themicroporous substrate 18 intolower processing chamber 16, and air flows throughport 34 and deforms the diaphragm inport 34 which would be vented to the atmosphere. Althoughport 34 is vented to the atmosphere there would be no passage of material between the interior of thecartridge 100 and the environment. This configuration permits back-and-forth transport of liquid across themicroporous substrate 18 by the periodic application of pressure to port 28 which can be vented to the atmosphere when pressure is not applied. - The
microporous substrate 18 serves as an interface betweenprocessing chambers processing chambers microporous substrate 18 when the critical pressure is exceeded.Head spaces 22 are produced inlower processing chamber 16 due tomicroporous substrate 18 projecting intolower processing chamber 16. WhileFIG. 1 shows two (2)head spaces 22 it will be understood that the cartridge may be configured to have only one. The direction of flow depends on the sign of the differential pressure betweenchambers -
Lower processing chamber 16 includes anoptical window 40 which forms part of the lower surface of thislower processing chamber 16 to allow imaging of themicroporous substrate 18 from outside thedevice cartridge 100. In those embodiments usingmicroporous substrate 18 which has been functionalized with binding agents and which imaging is to be performed throughoptical window 40,microporous substrate 18 is a rigid substrate disposed in a rigid plane parallel to the image plane of the imaging device such that it does not move or is not displaced which would result in poor quality images being detected. Preferred properties and structure ofrigid microporous substrate 18 will be discussed hereinafter. -
Upper process chamber 14 includes asolid support zone 44 which is the space immediately above themicroporous substrate 18 which can be occupied by a solid support material of a larger size than the pores in themicroporous substrate 18 such that the material is retained inzone 44 since it cannot pass through themicroporous substrate 18. The support material is capable of binding analytes of interest or acting as a support for reactions between bound and soluble materials. - A
capillary flow channel 48 connectsreagent chamber 10 with theupper processing chamber 14 and is designed with an inner diameter sized to prevent flow in either direction until a differential pressure is applied exceeding a preselected critical level to permit flow between thechambers capillary flow channel 50 connectsreagent chamber 12 with theupper processing chamber 14 and is designed with an inner diameter sized to prevent flow in either direction until a preselected differential pressure is applied exceeding the critical level to permit flow between thechambers capillary flow channel 52 connectslower processing chamber 16 with theoutlet chamber 20 and is designed with an inner diameter sized to prevent flow in either direction until a preselected differential pressure is applied exceeding the critical level to permit flow. For example, the capillary inner diameter could be selected from the range of 50 to 500 microns to provide critical pressures of 0.1 to 0.5 psi. - Flow is effected from one chamber to the next by applying pressure to the originating chamber containing the fluid through the pneumatic port mounted on that chamber while simultaneously venting the destination chamber to which the capillary channel is connected through the pneumatic port mounted on that chamber. Alternatively, negative differential pressure can be applied to the destination chamber while simultaneously venting the originating chamber. In both cases a sufficient pressure differential must be provided to overcome the resistance of the channel and allow flow to occur.
- In the case when a cycling of the fluid is required between two reagent chambers (e.g., for mixing) the differential pressure between these chambers can be changed from positive to negative and back to positive. This will change the direction of fluid flow.
-
Reagent chambers reagent chambers reagent chambers upper processing chamber 14, more could be included depending on the application at hand. Eachreagent chamber port 26 forchamber 10 andport 30 forchamber 12 which can be interfaced with an external pneumatic system capable of providing one or more of positive or negative pressures or venting to a given chamber under external control. - The
upper processing chamber 14 is provided withport 28 which can also be interfaced with an external pneumatic system capable of providing one or more of positive or negative pressures or venting to the chamber under external control. - The internal diameter of each
capillary channel capillary channel channel channels - The
upper processing chamber 14 is sized to exceed the total volume of reagents or sample fluids that may be transferred to theupper processing chamber 14 at any time. As seen inFIG. 1 ,capillary channel 48 connectingreagent chamber 10 toupper processing chamber 14 andcapillary channel 50 connectingreagent chamber 12 toupper processing chamber 14 are positioned so that they terminate in the upper portion of theupper processing chamber 14 such that all are above the maximum level of liquid reached in the chamber. The bottom of theupper processing chamber 14 is composed of themicroporous substrate 18 connected to the body of thechamber 14 in such a way that fluids can only exit through the bottom of thechamber 14 by passing through themicroporous substrate 18 when the differential pressure exceeds the critical pressure. - The
upper processing chamber 14 may also contain thesolid support 44 in the form of beads, particles, gels, or other similar materials that are capable of binding materials of interest from fluids within the chamber or acting as a support for bound materials to interact with materials contained in the fluid. Thesesolid support materials 44 are of sufficient size that they are retained by themicroporous substrate 18 and do not restrict flow through thesubstrate 18. - The
microporous substrate 18 may also be composed of a material or modified in such a way as to act as a solid support capable of binding materials of interest from fluids that pass between theupper processing chamber 14 and thelower processing chamber 16 or acting as a support for bound materials to interact with materials contained in the fluid. - The
microporous substrate 18 is constructed of material containing pores selected to provide a uniform resistance to flow across its entire surface such that at a defined pressure differential across thesubstrate 18, fluids will pass through the pores but gases (e.g., air) will not. The properties of the pores are selected such that the resistance to flow will not be overcome by the weight of liquids in theupper processing chamber 14 or allow capillary action to draw fluids completely through the pores insubstrate 18. The properties of themicroporous substrate 18 may optionally be selected to require a pressure differential to initiate flow that is in the same range as that required to initiate flow throughcapillaries upper processing chamber 14 and thelower processing chamber 16 is effected by applying pressure to theupper processing chamber 14 containing the fluid while simultaneously venting thelower processing chamber 16 separated by themicroporous substrate 18. - Alternatively, negative pressure can be applied to the
lower chamber 16 while simultaneously venting theupper chamber 14. In both cases the pressure differential must be provided in a range that is sufficient to overcome the resistance of the pores in thesubstrate 18 and allow flow of liquids to occur but below that required to overcome the resistance to the flow of air through the pores. The process may be reversed to effect flow in the opposite direction to allow repeated contact with thesubstrate 18 and anysolid support 44 contained in theupper chamber 14 as well as to provide efficient mixing. - The
lower processing chamber 16 is provided with two or more ports 34 (only one is shown inFIG. 1 ) which can be interfaced with an external pneumatic system capable of providing one or more of positive or negative pressures or venting to thechamber 16 under external control. Thelower processing chamber 16 has a volume equal to or greater than the maximum volume of reagents or sample fluids that may be transferred from thechamber 16 at any time. - The base of the
lower processing chamber 16 is positioned in close proximity to the lower surface of themicroporous substrate 18 while additional volume can be provided by extending a portion of thechamber 16 above the outer walls of theupper processing chamber 14 to form aheadspace 22. - The lower surface of the
lower processing chamber 16 which includes the opticallytransparent window 40 which allows for imaging of the lower surface of themicroporous substrate 18 using for example a charge coupled device (CCD) camera or other suitable optical sensor. - The
lower processing chamber 16 is connected to one ormore outlet chambers 20 by one or morecapillary channels 52 extending from the lowest point of thelower processing chamber 16 and terminating in the upper section of theoutlet chamber 20 at a point above the maximum level of liquid to be contained in theoutlet chamber 20. At least one of thesecapillary channels 52 is positioned at the lowest level of thechamber 16 to allow substantially all of the liquid in thechamber 16 to be removed throughchannel 52. - One
outlet chamber 20 may be used for waste containment in which case it is sized with a volume greater than the sum of all the fluids that need to be transferred from thelower processing chamber 16. Another outlet chamber (not shown) may be used to transfer fluids to additional downstream chambers for further processing, depending on the tests to be performed. - In addition to controlling the flow of the fluid, the
microporous substrate 18 alone or in combination with thesolid support 44 may be used to bind components in the fluid, and the bound components may be separated from the bulk fluid, washed, modified or copied, serve as binding agents for additional components, recovered for further use or any combination of these steps by the sequential transport of at least one fluid from a chamber on the device. - In addition to controlling the flow of the fluid, the
microporous substrate 18 may be designed to bind different substances in the fluid at different regions of thesubstrate 18, substances bound at different regions of thesubstrate 18 are subsequently detected and/or quantified. - A
single device 100 may contain one or more processing zones (two are shown as processingchambers integral microporous substrate 18 to accomplish different functions including analyte capture (nucleic acid, protein, small molecule other biological or chemical entities), modification of captured analyte (replication, extension, amplification, labeling, cleavage, hydrolysis), modification of soluble analytes through immobilized enzymes or catalysts, retention of solid matrix for higher capacity capture (beads, particles, gels), detection and/or quantitation of one or more captured analytes through optical imaging (colorimetric, fluorescent, chemiluminescent, bioluminescent). In all cases themicroporous substrate 18 also acts as a fluid control device necessary to carry out these functions. - The side views of
FIGS. 2 to 6 show side views of an actual cartridge produced using plastic in which a central plasticcartridge reagent plate 82 is sandwiched between anupper cartridge plate 80 and alower cartridge plate 84.FIG. 7 shows a photograph of an assembled cartridge andFIGS. 2 to 6 may be considered cross sections taken fromFIG. 7 . -
FIGS. 2 and 3 illustrate the dispensing of a liquid reagent or sample into theupper processing chamber 14. The liquid reagent orsample 60 is loaded into thereagent chamber 10 prior to the assay through a reagent/sample entry port 64 and then theport 64 is closed. A pressure of −1 psi is applied to thechamber 10 containing the liquid 60 viaport 26 whileport 28 connected to theupper processing chamber 14 is vented creating a pressure differential allowing the reagent to flow through thereagent capillary channel 48 intoupper processing chamber 14. The liquid 60 falls to the bottom of theupper processing chamber 14 and covers theintegral microporous substrate 18. Any excess air is allowed to vent throughport 28. This method of dispensing fluids is similar for all other reagent chambers used in the assay, with the exception of a bulk wash buffer (not shown) which is stored in a larger reservoir and metered through a capillary channel on a timed basis so that a precise volume can be delivered during dispensing. - Referring to
FIG. 4 , to pull the fluid through themicroporous substrate 18, a differential pressure is created by applying pressure throughport 28, while venting to atmosphere throughport 34. All other ports are closed during cycling.Fluid 60 travels from theupper processing chamber 14 into thelower process chamber 16 andheadspace 22. By applying a pressure differential above the critical pressure for liquid flow through themicroporous substrate 18 while not exceeding the critical pressure required for air flow through themicroporous substrate 18, flow continues until all liquid 60 is drawn from theupper processing chamber 14 and then stops. This design ensures that no air is drawn through, eliminating any bubbles that might interfere with processing or operation of the cartridge. - Referring to
FIG. 5 , to provide repeated contact withmicroporous substrate 18 alone or in combination with thesolid support 44 and to ensure efficient mixing, fluid 60 may be returned to theupper processing chamber 14 by reversing the process. A differential pressure is created by applying pressure to port 34 while simultaneously venting to atmosphere throughport 28. By applying a pressure differential above the critical pressure for liquid flow through themicroporous substrate 18 while not exceeding the critical pressure required for air flow through themicroporous substrate 18, flow continues until all liquid 60 is drawn from thelower processing chamber 16 back up toupper chamber 14 and then stops. This principle eliminates the need for any precise volumetric control of fluid flow and greatly simplifies control. The process of cycling back and forth through thesubstrate 18 can be repeated as many times as required. - Referring to
FIG. 6A , evacuation of the fluid from thelower processing chamber 16 is effected by applying a negative pressure throughport 36 onchamber 20 while venting to atmosphere throughport 34. This allows air to enter through thelower processing chamber 16headspace 22 and liquid 60 to travel though a distalwaste capillary channel 66 from one side oflower chamber 16 coupled to awaste inlet 76 which empties intochamber 20 and aproximal waste capillary 70 coupled to aproximal waste outlet 72 exiting from the other side ofchamber 16 coupled to awaste outlet 78 which empties liquid 60 intochamber 20. -
FIG. 6B shows an embodiment which is a kit including adisposable cartridge 100 along with adedicated blister pack 130 containing a plurality ofpackets 134 containing selected liquid assay reagents and a matchinggasket 132 with thepackets 134 containing the assay reagents being aligned with preselected reagent chambers in plasticcartridge reagent plate 82. The assembledcartridge 100 withupper cartridge plate 80 includes thepackets 134 partially projecting into their corresponding reagent chambers. When inserted into the instrument to implement the biological assay, applying pressure via the pneumatic system coupled to the pneumatic ports on plate 80 (not shown) of the various chambers results in rupturing of frangible seals in the blister pack resulting in the reagents flowing into their respective chambers. Thegasket 132 provides a liquid and gas seal between chambers. Additional solid reagents may be deposited into preselected reagent chambers within plasticcartridge reagent plate 82 prior to assembly ofcartridge 100, providing flexibility in the customization of reagent selection for desired biological assays and simplifying storage and transport requirements. - As noted above,
FIG. 7 is a photograph of an assembled cartridge showing five (5) reagent/sample chambers 10 connected to a centralupper processing chamber 14. This photograph shows the cartridge without the pneumatic connection to the cartridge. A nucleic acid bioassay (FIG. 25 ) and a protein bioassay (FIG. 26 ) were conducted using the assembled cartridge shown inFIG. 7 . - Analysis of nucleic acids usually requires processing steps to isolate nucleic acids and to derive labelled copies of them for subsequent detection. Many applications require the analysis of many different target sequences, and high analytical sensitivity is often required. Furthermore, automated, cost-effective systems will be required so that relatively unskilled people will be able to perform the tests reliably for routine clinical testing.
- Purification and amplification of multiple nucleic acids targets can be performed by capturing the nucleic acids on a solid support and performing a series of incubation and washing steps on the support to produce derivatives of the nucleic acids that can be analyzed by hybridization on nucleic acid probes arrayed on the microporous substrate.
-
FIG. 8 and its included legend shows a top view of a configuration of abioassay cartridge 200 which incorporates design ofcartridge 100 but is configured for both nucleic acid sample preparation and nucleic acid amplification (isothermal or polymerase chain reaction (PCR)) and multiplex detection of the products.Cartridge 200 is configured for both sample preparation using onemicroporous support 18 inprocessing chamber 209 and reaction product detection using a secondporous substrate 18 inprocessing chamber 224 each consisting of anupper processing chamber 14 and alower processing chamber 16 separated bymicroporous substrate 18. -
Cartridge 200 provides for asample inlet 208, a means to mix the sample with a lysis orpretreatment buffer 210, aprocessing chamber 209 containingmicroporous substrate 18 in which capture and modification of nucleic acids from the sample can be performed using dried or liquid reagents supplied fromchambers processing chamber 209 may be transferred towaste chamber 226 or in the case of fluid containing the derivative nucleic acids to athermal treatment chamber 211 orintermediate chamber 212. -
Chamber 212 may be used to mix the fluid with dried or liquid reagent inchamber 213. Subsequently, the fluid may be processed through one or moretemperature treatment chambers thermal treatment chambers zones 215 and controlled by the application of heat or cooling from an external thermal control assembly 108 (FIG. 9 ). The processed liquid containing the amplified derivative nucleic acids can then be transferred to anintermediate chamber 218, mixed with an appropriatebinding buffer 219 for hybridization to themicroporous substrate 18, located insample processing chamber 224 where the derivative nucleic acids are detected on bound nucleic acid probes immobilized in specific locations on themicroporous substrate 18. - A series of steps as previously described are carried out using reagents from
adjacent chambers waste chamber 227. In all cases pneumatic pressure applied through ports located on each chamber is used to control fluid movement. As a final step, an image of themicroporous substrate 18 is captured with a CCD camera with integral lens 120 (FIG. 10 ) located below the optical window 40 (FIG. 1 ). This image is analyzed for intensity of light measured across the microporous substrate and correlated to the specific regions known to contain the immobilized probes. This information is used to calculate the presence or absence or quantity of specific nucleic acids in the original sample. - Generally speaking, using the design principles disclosed above, cartridges may be configured to have multiple reagent/sample chambers/reservoirs, upper and
lower processing chambers waste chambers 20. For example,waste chamber 20 may in fact be an intermediate chamber accepting reaction products from a first processing station including first and second upper andlower processing chambers chamber 20 forming a sample chamber for a second series of upper andlower processing chambers cartridge 200 may be configured with additional features to permit numerous intermediate processing steps to be carried out between the first and second set of upper andlower processing chambers Optionally cartridge 200 may include adecontamination chamber 228 containing a cleansing agent selected to destroy or neutralize harmful products of the assay or sample. - The system of
FIG. 8 utilizing the disposable cartridge disclosed herein is very amenable to performing the above noted nucleic acid assay such as that disclosed in United States Patent Publication Serial No. US2018-0057855A1, which is incorporated herein by reference in its entirety, and which is a national phase entry patent application of PCT/2016/050367 filed on Mar. 29, 2016. Thus, the present disclosure provides a cartridge which in an embodiment comprises two different microporous substrates each with upper and processing chambers, one of which is a solid support for purification of multiple target nucleic acids and processing of the target nucleic acids to produce derivative nucleic acids, and the other of which is a porous substrate on which the derivative nucleic acids are detected on bound nucleic acid probes. The present cartridge, in conjunction with an instrument designed to operate it, will accept samples and provide clinically relevant information without user intervention after inserting the samples. - Analysis of proteins in biological samples (e.g., human serum) by immuno-binding reactions often requires dilution of the samples before the immuno-binding reactions. The present disclosure provides embodiments of a disposable cartridge comprising two
different microporous substrates 18 each with associated upper andlower processing chambers chambers chambers microporous substrate 18 on which the proteins are detected by immuno-binding reactions. - Specific volumes of the sample and of the diluent are transported to the
upper processing chamber 14 above thefirst microporous support 18, and they are mixed by passing the solution through theporous substrate 18 into thelower processing chamber 16, and are pneumatically cycled or driven back and forth between thechambers lower processing chamber 16 to the secondbuffer processing chamber 14 above thesecond microporous substrate 18 for detection on thesecond microporous substrate 18. Thefirst microporous substrate 18 may contain immobilized binding agents that would bind specific components in the sample. For example, interfering substances might be removed by binding to thefirst microporous substrate 18 before the immuno-binding step on the secondporous substrate 18 is performed. - In another instance, low abundance substances may be concentrated from a large volume by binding to the
first microporous substrate 18 and then being released in a smaller volume at higher concentration before the immuno-binding step on thesecond microporous substrate 18 is performed in order to improve overall sensitivity of detection. -
FIG. 9 shows a partially exploded view of thedisposable cartridge 104 sandwiched between an upper pneumaticblock assembly interface 106 and a lowerthermal control assembly 108 which form part of the instrument into which thecartridge 104 is inserted.Pneumatic interface 106 includes all the requisite pneumatic coupling components, tubes and the like needed to couple to the pneumatic ports of thecartridge 104. All these components are housed ininterface 106 and do not form part of thedisposable cartridge 104. - Similarly,
thermal control assembly 108 contains all requisite features such as heaters, temperatures sensors and associated controllers, microprocessors and the like to control the temperature in selected zones of thecartridge 104. Thethermal control assembly 108 includes acentral aperture 110 which when assembled withcartridge 104 aligns withoptical window 40 to allow imaging of theporous substrate 18.FIG. 10 is a partial cross-sectional view of the sandwiched structure ofFIG. 9 showing detector 120 positioned to view thismicroporous substrate 18 in the assembled system.Detector 120 which includes an appropriate objective lens is configured to image the bottom side ofmicroporous substrate 18 to detect the presence of colorimetric, fluorescent, chemiluminescent, or bioluminescent signals. - A preferred material from which the
microporous substrate 18 is produced is silicon which is rigid and opaque to chemiluminescent emission. This opacity prevents crosstalk between different pores of the substrate and hence prevents crosstalk between closely spaced regions on the substrate with different binding agents. This permits the analysis of many analytes in a small device, since different binding agents can be arranged in close proximity. As an example, the substrate may contain pores with a size in the range of 1 to 15 microns with wall thicknesses between pores ranging from 1 to 5 microns. - Referring to
FIGS. 11A to 14C inclusive, in an embodiment of themicroporous substrate 18, the two opposed sides have different pore sizes. The side of thesubstrate 18 from which light is collected to enable detection and analysis has substantially wider pores as can be seen inFIGS. 11A to 14C , and this side is the side facing intolower reaction chamber 16 and faces theoptical window 40 from which the detector 120 (FIG. 10 ) is spaced. As can be appreciated fromFIGS. 11A to C, the walls of the pores at this surface are tapered rather than being normal to the surface. This geometry presents a greater surface area to the detection optics and less restriction to the transmission of light from within the pores. Despite the large pores on a front surface and great porosity, thesubstrate 18 has adequate strength and structural stability for flow-through applications due to the small pore size on the opposite side and there is a substantial amount of material between the pores. - The remarkable asymmetric optical properties of the substrate are illustrated in
FIGS. 15A and B. Specifically,FIGS. 15A and 15B demonstrate the improvement in light transmission of a porous substrate due to pore tapering. The same substrate is shown in 15A and 15B when illuminated by the same diffuse light source. The widened part of the pores are facing the objective lens inFIG. 15A and the narrow part of the pores are facing the objective lens inFIG. 15B . The spots on the substrates are regions in which the pores of the substrate have been blocked with probe solutions that have dried in the pores. - Tapering of the pore walls provides improvement of light collection due to increase of the depth from which the light can be collected, increase of the emitting surface area of the upper portion of a pore and increase of a collection angle. These mechanisms of light collection efficiency are illustrated in
FIGS. 16A to 16C with 16A showing the effect of increasing of the effective depth; 16B showing the effect of an increase in the collection angle; and 16C showing the effect of increase of surface area. - The results of the evaluation of these effects for a particular implementation of the method described in this application are shown in
FIG. 17 which shows the results of calculation of light collection efficiency as a function of pore depth for a straight 8 um pore (plot A) and a pore with tapered walls (plot B). The parameters used for this evaluation are: 1) the width of non-tapered portion of a pore is 8 um; 2) the thickness of a wall between pores is 4 um; 3) the substrate thickness is 350 um; 4) taperingangle 2 degrees; 5) the diameter of the objective lens is 25.4 mm; and 6) the working distance of the objective lens is 50 mm. - In
FIG. 17 the rise of the flat part of the curve is caused by increase of the collection surface area, the shift of the curve is caused by increase of the pore depth from which the light collection is limited by the parameters of the optical assembly rather than the pore walls, the change in a slope of the curve is associated with a change of the collection angle. As a result, the expected improvement of light collection efficiency is 1.4 to 1.5 fold. - The
substrate 18 using silicon has been used to manufacture flow-through chips on which different probes have been immobilized in discrete regions or spots. The same flow-through chips have been manufactured with a highly microporous silicon substrate with pore walls normal to the surface. When these flow-through chips were hybridized with the same target molecules and processed with identical protocols to detect chemiluminescent labels attached to target molecules bound by the probes, the signal intensities were approximately 40% greater with the substrate described in this invention (FIG. 18 ). This experimental result confirms the theoretical evaluation of efficiency enhancement due to pore tapering. The enhanced optical detection sensitivity improves the sensitivity of assays performed on the chips and/or improves the throughput of the assay system. - The suggested approach is not very sensitive to a particular selection of the tapering angle as long as the inner plane of a pore wall does not restrict light collection. For the parameters listed above the tapering angle can be selected in the range between 0.3 degrees (tapering of a pore wall along full pore depth) to approximately 14 degrees. Tapering with the angles outside of this range will still increase amount of collected light, but the improvement will be less pronounced. It is noted that selection of a particular tapering angle and depth of tapering can be additionally influenced by the process of substrate manufacturing, the selected pore size and membrane thickness.
- The geometry of pores does not need to be square. If the manufacturing process requires they may have a different cross section, for example, circular. In this case the pore is cylindrical (see
FIGS. 19A, 19B to 21A, 21B inclusive). In this case the simplest form of tapering is conical as shown inFIGS. 19A and 19B . The light collection efficiency can be additionally increased by changing shape of tapering from conical to spherical (seeFIGS. 20A and 20B ) or parabolic (FIGS. 21A and 21B ). - Pores of different cross section (circular, square, polygonal) were derived to practice: the micro photographs of such silicon substrates are shown in
FIGS. 13A to 13C . The light collection efficiency can be additionally improved for a substrate with cylindrical pores by a denser arrangement of pores as shown inFIG. 22B compared to the collection efficiency of the packed structure ofFIG. 22A . - The structural stability of the substrate material depends on the type of material (e.g., silicon or plastic) and its thickness. If the substrate is thin or/and the material is flexible or soft, a reinforcement frame can be used to strengthen the substrate (see
FIGS. 23 and 24 ). Referring toFIG. 23 , asubstrate 300 can be attached to a single frame 310 made of ribs 304 with the single frame being integrally formed with thesubstrate 300 or, preferably sandwiched between two separate frames 324 and 326 (seeFIG. 24 ), which are separate from thesubstrate 300, to allow bidirectional application of pressure required to drive fluids through the porous substrate as described above without damaging of the substrate. - in conclusion, the present disclosure provides a disposable sample handling cartridge for performing multiplex biological assays in which the cartridge is designed and configured to provide complex fluid processing without the need for active pumping and valving. The cartridge is readily produced using standard molding techniques, no nanostructrures are required and no precise tolerances are required. The movement of sample and reagent fluid is solely determined by application of differential pressures, which are correlated primarily with the properties of the
sample substrate 18, namely pore size and distribution in thesubstrate 18, as well as the inner diameter of the capillary channels (e,g. 48). The cartridge disclosed herein advantageously contains no moving parts and is made of a small number of parts compared to current systems, which typically contain active pumps, active valves and the like. - The cartridge disclosed herein may be used for, but is not limited to use in sandwich, or competitive immunoassay for protein antigen analysis; serology for antibody binding to immobilized antigens for allergy, autoimmune, infectious disease; nucleic acids measurement of DNA, RNA, mRNA, microRNA (miRNA) etc. to identify specific sequences whose presence or expression is correlated to presence or progress of disease, sequences that can be used to identify species of bacteria, fungi, viruses in a sample, sequences that indicated the presence of specific resistance genes in pathogens, measurement of copy number variations (CNV's) or specific gene variants or deletions that correlate to risk of disease, gene signatures used to type samples for forensic or identification purposes. In addition, it may be used for small molecule measurements including drugs and environmental contaminants. It may also be used in multiple sample matrices including human and animal fluids and tissues, food and agricultural samples, environmental samples, cells and lysates of cells, and bioprocessing fluids.
- Non-limiting exemplary uses of the disposable cartridge disclosed herein will now be given using a nucleic acid assay and a protein assay.
-
FIG. 25A shows results of a nucleic acid bioassay wherein a sample containing biotin labelled PCR products representing copies of specific gene sequences from bacterial samples were processed using the cartridge shown inFIG. 7 . Prior to assembly of the cartridge, themicroporous substrate 18 was functionalized in discrete regions to form analysis spots, each of approximately 200 um in diameter, with oligonucleotide probes containing sequences complementary to sequences known to occur in the amplified bacterial gene (+ve Probes 1, 2, 3, 4), sequences not known to occur in the amplified bacterial gene (−veProbes 1, 2) or a sequence complementary to an artificial oligonucleotide added to the sample (Fiducial). In addition, one blank spot where no oligonucleotide probe was immobilized was used as a control to measure background signal. 5individual reagent wells 10 and abulk chamber 87 were used. - The reagent chambers were individually loaded with blocking buffer, hybridization buffer, sample, streptavidin-HRP and chemiluminescent substrate respectively. The
bulk reservoir 87 was loaded with wash buffer. Reagents were transferred to the upper processing chamber in individual steps as illustrated inFIG. 3 . Each liquid was then transferred to the lower processing chamber as illustrated inFIG. 4 and then returned to the upper processing chamber as illustrated inFIG. 5 . - After repeating this cycle back and forth through the
microporous substrate 18 as many times as required for each step the reagent was removed to waste chamber as illustrated inFIG. 6 . Between each step an aliquot of wash buffer frombulk chamber 87 was similarly processed. The sequential steps accomplished blocking of the porous microporous substrate to prevent non-specific binding, hybridization of PCR products in the sample to the probes containing complementary sequences immobilized in discrete regions onporous substrate 18, binding of streptavidin-HRP to the biotin label on captured PCR products, and introduction of a chemiluminescent substrate that could be processed by the captured HRP enzyme to produce a chemiluminescent emission in that specific region. - During the final step, an image of the
microporous substrate 18 was captured with aCCD camera 120 located below theoptical window 40. This imageFIG. 25B was analyzed for intensity of light measured across themicroporous substrate 18 and correlated to the specific regions known to contain the immobilized probes.FIG. 25A shows the luminescent intensity for three repeats of the bioassay for the same sample. It will be noted that significant signals are observed on analysis spots formed by immobilizing probes containing complementary sequences to gene sequences expected in the sample (+ve Probes 1, 2, 3, 4), minimal signal is observed on analysis spots formed by immobilizing probes containing complementary sequences to gene sequences not expected in the sample (−veProbes 1, 2). As expected, no signal was observed on the blank analysis spot, and substantial signal was observed on the analysis spot containing a complementary sequence to the artificial oligonucleotide added to the sample prior to analysis. -
FIG. 26 shows results of protein bioassays on human serum or control buffer to determine the presence of antibodies against the measles virus carried out using the cartridge pictured inFIG. 7 . Prior to assembly of the cartridge, themicroporous substrate 18 was functionalized in discrete regions to form analysis spots, each of approximately 200 um in diameter, with a deactivated measles virus preparation. Four reagent chambers were individually loaded with blocking buffer, sample, HRP labelled anti human immunoglobulin G and chemiluminescent substrate, respectively. Thebulk reservoir 87 was loaded with wash buffer. - Reagents were transferred to the upper processing chamber in individual steps as illustrated in
FIG. 3 . Each liquid was then transferred to the lower processing chamber as illustrated inFIG. 4 and then returned to the upper processing chamber as illustrated inFIG. 5 . After repeating this cycle back and forth through themicroporous substrate 18 as many times as required for each step the reagent was removed to waste chamber as illustrated inFIG. 6 . Between each step an aliquot of wash buffer frombulk chamber 87 was similarly processed. The sequential steps accomplished blocking of the microporous substrate to prevent non-specific binding, binding from the sample of any immunoglobulins containing regions that are specific to components of the measles virus immobilized in discrete regions onmicroporous substrate 18, binding of anti-human immunoglobulin G antibody coupled to a HRP enzyme to any retained anti-measles immunoglobulins, and introduction of a chemiluminescent substrate that could be processed by the bound HRP enzyme to produce a chemiluminescent emission in that specific region. - During the final step, an image of the
microporous substrate 18 was captured with aCCD camera 120 located below theoptical window 40. This image was analyzed for intensity of light measured across themicroporous substrate 18 and correlated to the specific regions known to contain the immobilized virus. The chart inFIG. 26 shows the luminescence intensity recorded for three types of samples. It will be noted that significant signal corresponding to the presence of measles specific antibodies is observed from the serum sample drawn from a patient known to have immunity to the measles virus (positive serum). Significantly lower signal is observed from serum drawn from a patient known to have reduced immunity to the measles virus (negative serum). Minimal signal is observed from a control buffer sample that does not contain any measles specific antibodies. -
FIG. 27A illustrates the results of a process that utilizes two different microporous substrates each with upper and processing chambers, one of which is a solid support for capture of protein analytes, and the other of which is a microporous substrate on which the protein analytes are detected on bound protein specific receptors. In this example, identical samples containing biotinylated mouse IgG analyte were cycled through amicroporous substrate 18 that was functionalized with a rabbit anti-mouse antibody know to have a high binding affinity for mouse IgG (Treated sample) or cycled through amicroporous substrate 18 that had not been functionalized, (Non-treated sample). - The resulting fluid was then processed through a microporous substrate that had been functionalized in discrete regions to form analysis spots, each of approximately 200 um in diameter with either a rabbit anti-mouse antibody known to have a high binding affinity for mouse IgG or a biotinylated bovine serum albumin to serve as a reference spot. Washing, binding of streptavidin-HRP to any captured biotin-mouse IgG and immobilized biotin-BSA, and introduction of a chemiluminescent substrate that could be processed by the bound HRP enzyme to produce a chemiluminescent emission in that specific region were sequentially carried out. During the final step, an image of the
microporous substrate 18 was captured with aCCD camera 120 located below theoptical window 40. The intensity of each spot functionalized with rabbit anti-mouse IgG correlates with the amount of biotinylated mouse IgG analyte present in the solution. -
FIG. 27A shows that the sample that had been processed by the first functionalized microporous substrate 18 (Treated) was almost completely depleted of mouse IgG analyte when processed on thesecond microporous substrate 18 used for detection. It can also be observed that the sample that had been processed by the first non-functionalized microporous substrate 18 (non-treated) exhibited high levels of mouse IgG analyte when processed on thesecond microporous substrate 18 used for detection. -
FIG. 27B represents the signal captured by theCCD camera 120 from thesecond microporous substrate 18 for the treated sample. Significant signal is observed only on the reference biotinylated BSA analysis spots.FIG. 27C represents the signal captured by theCCD camera 120 from thesecond microporous substrate 18 for the non-treated sample. Significant signal from the analysis spots for both the reference biotinylated BSA and the biotinylated mouse IgG can be observed. This illustrates the high efficiency of using afirst microporous substrate 18 functionalized with analyte specific reagents to deplete those analytes prior to detection and quantitation on asecond microporous substrate 18. As an example, this may have utility in removing or depleting substances that may interfere with analysis on thesecond microporous substrate 18.
Claims (20)
1. A microporous substrate for detection of surface bound target analyte molecules, comprising:
a microporous substrate material having opposed surfaces and micropores, the micropores having bound therein analyte specific receptors complementary to the target analyte molecules, the micropores having tapered walls extending through a thickness of said microporous substrate in which the micropores are wider near one surface of the microporous substrate compared to a width of the micropores on the opposed surface to increase the collection efficiency of light emitted from optical probes bound to target analyte molecules when the target analyte molecules are captured by the analyte specific receptors which is detected by a light detector spaced from the side of the microporous substrate facing the larger micropore openings compared to a light collection efficiency of light emitted from the optical probes when the micropores are straight and not tapered.
2. The microporous substrate according to claim 1 , wherein the micropores are progressively wider near one surface of the microporous substrate.
3. The microporous substrate according to claim 1 , wherein the micropores have a rectangular cross section.
4. The microporous substrate according to claim 1 , wherein the micropores have a square cross section.
5. The microporous substrate according to claim 1 , wherein the micropores have a circular cross section.
6. The microporous substrate according to claim 1 , wherein in which tapering of the micropore walls is conical, spherical, or parabolic.
7. The microporous substrate according to claim 1 , wherein a micropore dimension on the side opposite the side of the widened micropores are substantially smaller thereby providing structural stability.
8. The microporous substrate according to claim 1 , wherein the micropores are of uniform dimensions and morphology.
9. The microporous substrate according to claim 1 , further comprising reinforcement ribs to provide structural stability.
10. The microporous substrate according to claim 9 , wherein the reinforcement ribs are an integral part of the microporous substrate.
11. The microporous substrate according to claim 9 , wherein the reinforcement ribs are separate from the microporous substrate and made in a form of a rigid supporting mesh.
12. The microporous substrate according to claim 11 , wherein said microporous substrate is attached to a supporting mesh placed on the surface of said microporous substrate having the smaller micropore openings.
13. The microporous substrate according to claim 12 , wherein said microporous substrate is placed between two supporting meshes placed on the opposite sides of said microporous substrate.
14. The microporous substrate according to claim 1 , wherein the microporous substrate has a thickness of between 0.15 to about 0.75 mm.
15. The microporous substrate according to claim 1 , wherein the tapered surface of a micropore is covered with a reflective coating.
16. The microporous substrate according to claim 1 , wherein the microporous substrate is made of silicon.
17. The microporous substrate according to claim 1 , wherein the microporous substrate is made of a material that is opaque such that light from one micropore cannot be transmitted to neighboring micropores with the microporous substrate.
18. The microporous substrate according to claim 1 , wherein the microporous substrate is generally planar.
19. A method for manufacturing the microporous substrate according claim 1 , comprising:
performing electrochemical etching of silicon to manufacture the microporous substrate.
20. A method for manufacturing the microporous substrate according claim 1 , comprising:
embossing or molding of a plastic material to manufacture the microporous substrate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/886,710 US20230001407A1 (en) | 2015-04-09 | 2022-08-12 | Microporous substrate for use in a disposable bioassay cartridge |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562145330P | 2015-04-09 | 2015-04-09 | |
US201562165347P | 2015-05-22 | 2015-05-22 | |
PCT/CA2016/050414 WO2016161524A1 (en) | 2015-04-09 | 2016-04-11 | Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge |
US201715564791A | 2017-10-06 | 2017-10-06 | |
US15/902,030 US11305274B2 (en) | 2015-04-09 | 2018-02-22 | Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge |
US17/716,729 US20220226810A1 (en) | 2015-04-09 | 2022-04-08 | Microporous substrate for use in a disposable bioassay cartridge |
US17/886,710 US20230001407A1 (en) | 2015-04-09 | 2022-08-12 | Microporous substrate for use in a disposable bioassay cartridge |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/716,729 Continuation US20220226810A1 (en) | 2015-04-09 | 2022-04-08 | Microporous substrate for use in a disposable bioassay cartridge |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230001407A1 true US20230001407A1 (en) | 2023-01-05 |
Family
ID=57071623
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,791 Active 2036-09-11 US10946375B2 (en) | 2015-04-09 | 2016-04-11 | Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge |
US15/902,030 Active US11305274B2 (en) | 2015-04-09 | 2018-02-22 | Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge |
US17/178,663 Pending US20210237050A1 (en) | 2015-04-09 | 2021-02-18 | Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge |
US17/716,729 Pending US20220226810A1 (en) | 2015-04-09 | 2022-04-08 | Microporous substrate for use in a disposable bioassay cartridge |
US17/886,710 Pending US20230001407A1 (en) | 2015-04-09 | 2022-08-12 | Microporous substrate for use in a disposable bioassay cartridge |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/564,791 Active 2036-09-11 US10946375B2 (en) | 2015-04-09 | 2016-04-11 | Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge |
US15/902,030 Active US11305274B2 (en) | 2015-04-09 | 2018-02-22 | Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge |
US17/178,663 Pending US20210237050A1 (en) | 2015-04-09 | 2021-02-18 | Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge |
US17/716,729 Pending US20220226810A1 (en) | 2015-04-09 | 2022-04-08 | Microporous substrate for use in a disposable bioassay cartridge |
Country Status (7)
Country | Link |
---|---|
US (5) | US10946375B2 (en) |
EP (2) | EP3683578A1 (en) |
JP (2) | JP6787924B2 (en) |
CN (2) | CN110665557B (en) |
CA (3) | CA2981990A1 (en) |
HK (1) | HK1250784A1 (en) |
WO (1) | WO2016161524A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106872684B (en) * | 2017-03-27 | 2018-11-02 | 厦门先明生物技术有限公司 | Integrated reagent set parallel processing reaction unit |
EP3621736B1 (en) | 2017-05-11 | 2021-08-18 | Cytochip Inc. | Reagent packaging devices |
AU2021358962B2 (en) * | 2020-10-07 | 2025-01-30 | Massachusetts Institute Of Technology | Microfluidic cell culture devices |
CN114015552B (en) * | 2021-11-04 | 2022-06-07 | 贵州医科大学附属医院 | Kit for identifying human mesenchymal stem cells |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756884A (en) * | 1985-08-05 | 1988-07-12 | Biotrack, Inc. | Capillary flow device |
DE4202454C1 (en) | 1992-01-29 | 1993-07-29 | Siemens Ag, 8000 Muenchen, De | |
US5458852A (en) * | 1992-05-21 | 1995-10-17 | Biosite Diagnostics, Inc. | Diagnostic devices for the controlled movement of reagents without membranes |
US5423581A (en) * | 1993-03-31 | 1995-06-13 | Salyers; Marshall L. | Low carryover fitting and method for coupling tubing to a device using the same |
WO1995011755A1 (en) * | 1993-10-28 | 1995-05-04 | Houston Advanced Research Center | Microfabricated, flowthrough porous apparatus for discrete detection of binding reactions |
DE4435107C1 (en) * | 1994-09-30 | 1996-04-04 | Biometra Biomedizinische Analy | Miniaturized flow thermal cycler |
US5882496A (en) | 1997-02-27 | 1999-03-16 | The Regents Of The University Of California | Porous silicon structures with high surface area/specific pore size |
AU724382B2 (en) | 1997-07-11 | 2000-09-21 | Pamgene B.V. | A device for performing an assay, a method for manufacturing said device, and use of a membrane in the manufacture of said device |
US6167910B1 (en) * | 1998-01-20 | 2001-01-02 | Caliper Technologies Corp. | Multi-layer microfluidic devices |
CN1326549A (en) | 1998-10-13 | 2001-12-12 | 微生物系统公司 | Fluid circuit components based upon passive fluid dynamics |
GB9907665D0 (en) * | 1999-04-01 | 1999-05-26 | Cambridge Molecular Tech | Fluidic devices |
DE19919903A1 (en) * | 1999-04-30 | 2000-11-02 | Nft Nano Filtertechnik Gmbh | Process for making a filter |
ATE364843T1 (en) | 1999-08-11 | 2007-07-15 | Asahi Chemical Ind | ANALYSIS CASSETTE AND FLUID FEED CONTROLLER |
US6383748B1 (en) | 1999-09-14 | 2002-05-07 | Pamgene B.V. | Analytical test device with substrate having oriented through going channels and improved methods and apparatus for using same |
JP3715148B2 (en) * | 1999-09-17 | 2005-11-09 | 富士写真フイルム株式会社 | High density macro array |
US7326561B2 (en) | 1999-12-22 | 2008-02-05 | Jack Goodman | Flow-thru chip cartridge, chip holder, system and method thereof |
US6770322B1 (en) | 2000-03-03 | 2004-08-03 | Ysi Incorporated | Method of making a platform for use in a sensor in a microfluidic device |
US7470546B2 (en) | 2000-05-31 | 2008-12-30 | Infineon Technologies Ag | Method and arrangement for taking up a first medium, which is present in a first phase, into a capillary device |
US7163660B2 (en) | 2000-05-31 | 2007-01-16 | Infineon Technologies Ag | Arrangement for taking up liquid analytes |
CA2425476C (en) * | 2000-10-10 | 2011-02-01 | Biotrove, Inc. | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
US6886409B2 (en) | 2001-03-13 | 2005-05-03 | Pamgene International B.V. | System for controlling the flow of a fluid through a substrate |
US6418968B1 (en) | 2001-04-20 | 2002-07-16 | Nanostream, Inc. | Porous microfluidic valves |
WO2003011553A1 (en) * | 2001-07-31 | 2003-02-13 | Massachusetts Institute Of Technology | On-chip membrane maker |
US7166443B2 (en) * | 2001-10-11 | 2007-01-23 | Aviva Biosciences Corporation | Methods, compositions, and automated systems for separating rare cells from fluid samples |
JP2003166910A (en) | 2001-11-30 | 2003-06-13 | Asahi Kasei Corp | Liquid-feeding mechanism and analyzer provided with the same |
US20050241477A1 (en) * | 2002-03-05 | 2005-11-03 | Mundschau Michael V | Hydrogen transport membranes |
DE10217568A1 (en) * | 2002-04-19 | 2003-11-13 | Infineon Technologies Ag | Waveguides in porous substrates |
US20040042930A1 (en) | 2002-08-30 | 2004-03-04 | Clemens Charles E. | Reaction chamber with capillary lock for fluid positioning and retention |
US6806543B2 (en) | 2002-09-12 | 2004-10-19 | Intel Corporation | Microfluidic apparatus with integrated porous-substrate/sensor for real-time (bio)chemical molecule detection |
US7279134B2 (en) * | 2002-09-17 | 2007-10-09 | Intel Corporation | Microfluidic devices with porous membranes for molecular sieving, metering, and separations |
TW590982B (en) | 2002-09-27 | 2004-06-11 | Agnitio Science & Technology I | Micro-fluid driving device |
JP4027218B2 (en) | 2002-12-13 | 2007-12-26 | キヤノン株式会社 | Filtration membrane manufacturing method |
JP4795626B2 (en) | 2003-03-04 | 2011-10-19 | 紀夫 寺前 | Method for producing porous film and thin film |
GB0311902D0 (en) * | 2003-05-22 | 2003-06-25 | Cambridge Life Sciences | Assay method and apparatus |
US20040265171A1 (en) | 2003-06-27 | 2004-12-30 | Pugia Michael J. | Method for uniform application of fluid into a reactive reagent area |
DE102004034486B4 (en) * | 2004-07-16 | 2007-08-23 | Infineon Technologies Ag | Method for detecting luminescent light from a porous support structure |
JP4683633B2 (en) * | 2004-11-09 | 2011-05-18 | キヤノン株式会社 | Liquid analysis system and cartridge |
JP4623716B2 (en) | 2004-11-25 | 2011-02-02 | 旭化成株式会社 | Nucleic acid detection cartridge and nucleic acid detection method |
WO2006132324A1 (en) * | 2005-06-10 | 2006-12-14 | Olympus Corporation | Reaction container and reaction apparatus employing the same |
JP2009500602A (en) * | 2005-06-30 | 2009-01-08 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Fluid analysis apparatus and method |
JP2007097444A (en) * | 2005-09-30 | 2007-04-19 | Bussan Nanotech Research Institute Inc | Inspection chip |
JP4231869B2 (en) * | 2005-12-09 | 2009-03-04 | シャープ株式会社 | Biochemical sensor and measuring device |
GB2456079B (en) * | 2007-08-17 | 2010-07-14 | Diagnostics For The Real World | Device, system and method for processing a sample |
EP2070594A1 (en) * | 2007-12-14 | 2009-06-17 | Koninklijke Philips Electronics N.V. | Microfluidic device and method of making the same and sensor incorporating the same |
WO2009078107A1 (en) * | 2007-12-19 | 2009-06-25 | Shimadzu Corporation | Dispensing device |
WO2010005467A2 (en) | 2008-07-09 | 2010-01-14 | Micropoint Bioscience Inc | Analytical cartridge with fluid flow control |
US9919311B2 (en) * | 2009-07-20 | 2018-03-20 | Siloam Biosciences, Inc. | Microfluidic assay platforms |
US8512588B2 (en) * | 2010-08-13 | 2013-08-20 | Lawrence Livermore National Security, Llc | Method of fabricating a scalable nanoporous membrane filter |
EP2622321A4 (en) * | 2010-10-01 | 2014-03-19 | 3M Innovative Properties Co | Portable monitor for end of service life indication |
JP6019485B2 (en) * | 2011-03-24 | 2016-11-02 | ベーリンガー インゲルハイム マイクロパーツ ゲゼルシャフト ミット ベシュレンクテル ハフツングBoehringer Ingelheim microParts GmbH | Blood filtration instrument and method |
US20130032235A1 (en) * | 2011-08-02 | 2013-02-07 | Teledyne Dalsa Semiconductor, Inc. | Integrated microfluidic check valve and device including such a check valve |
WO2014182847A1 (en) * | 2013-05-07 | 2014-11-13 | Micronics, Inc. | Device for preparation and analysis of nucleic acids |
GB2516675A (en) * | 2013-07-29 | 2015-02-04 | Atlas Genetics Ltd | A valve which depressurises, and a valve system |
US11060131B2 (en) | 2015-03-25 | 2021-07-13 | Angle Europe Limited | Solid phase nucleic acid target capture and replication using strand displacing polymerases |
-
2016
- 2016-04-11 CA CA2981990A patent/CA2981990A1/en active Pending
- 2016-04-11 JP JP2017552871A patent/JP6787924B2/en not_active Expired - Fee Related
- 2016-04-11 US US15/564,791 patent/US10946375B2/en active Active
- 2016-04-11 EP EP20159555.0A patent/EP3683578A1/en not_active Withdrawn
- 2016-04-11 WO PCT/CA2016/050414 patent/WO2016161524A1/en active Application Filing
- 2016-04-11 CA CA3162752A patent/CA3162752A1/en active Pending
- 2016-04-11 CA CA3162780A patent/CA3162780A1/en active Pending
- 2016-04-11 CN CN201910954662.5A patent/CN110665557B/en not_active Expired - Fee Related
- 2016-04-11 CN CN201680027156.6A patent/CN107615064B/en not_active Expired - Fee Related
- 2016-04-11 EP EP16775992.7A patent/EP3281009A4/en not_active Withdrawn
-
2018
- 2018-02-22 US US15/902,030 patent/US11305274B2/en active Active
- 2018-08-08 HK HK18110185.4A patent/HK1250784A1/en unknown
-
2019
- 2019-04-11 JP JP2019075353A patent/JP7123848B2/en active Active
-
2021
- 2021-02-18 US US17/178,663 patent/US20210237050A1/en active Pending
-
2022
- 2022-04-08 US US17/716,729 patent/US20220226810A1/en active Pending
- 2022-08-12 US US17/886,710 patent/US20230001407A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016161524A1 (en) | 2016-10-13 |
CN107615064A (en) | 2018-01-19 |
US20180117582A1 (en) | 2018-05-03 |
CA3162780A1 (en) | 2016-10-13 |
US20190054460A1 (en) | 2019-02-21 |
EP3281009A4 (en) | 2018-11-14 |
US20220226810A1 (en) | 2022-07-21 |
EP3281009A1 (en) | 2018-02-14 |
EP3683578A1 (en) | 2020-07-22 |
US20210237050A1 (en) | 2021-08-05 |
CN110665557B (en) | 2022-08-23 |
JP6787924B2 (en) | 2020-11-18 |
CN110665557A (en) | 2020-01-10 |
JP2019164140A (en) | 2019-09-26 |
CA2981990A1 (en) | 2016-10-13 |
US11305274B2 (en) | 2022-04-19 |
CA3162752A1 (en) | 2016-10-13 |
JP7123848B2 (en) | 2022-08-23 |
US10946375B2 (en) | 2021-03-16 |
HK1250784A1 (en) | 2019-01-11 |
CN107615064B (en) | 2020-02-28 |
JP2018517891A (en) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10532352B2 (en) | Sample analysis system | |
JP6838127B2 (en) | Test cartridge with integrated transfer module | |
US20230001407A1 (en) | Microporous substrate for use in a disposable bioassay cartridge | |
US11813609B2 (en) | Microfluidic cartridge for molecular diagnosis | |
KR20140110925A (en) | Microfluidic reactor system | |
US20090093064A1 (en) | Method of determining the presence of a mineral within a material | |
CN108344876B (en) | Microfluidic measurement device and measurement method using the same | |
US20240353439A1 (en) | Fluidic bridge device and sample processing methods | |
WO2007055165A1 (en) | Method of separating nucleic acid, microreactor for testing nucleic acid and nucleic acid test system | |
US20030224371A1 (en) | Integrated cartridge for sample manipulation | |
US12275009B2 (en) | Microfluidic cartridge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ANGLE EUROPE LIMITED, ENGLAND Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:AXELA INC.;REEL/FRAME:061164/0683 Effective date: 20180613 Owner name: AXELA INC., ONTARIO Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNORS:IZMAILOV, ALEXANDRE;ENGLERT, DAVID;SMITH, PAUL;SIGNING DATES FROM 20160602 TO 20160607;REEL/FRAME:060796/0541 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |